Understanding the *in vitro* gastrointestinal transit tolerance of putative lactic acid bacteria isolated from Malaysian fermented foods.

Low Siew Jean

Thesis submitted to the University of Nottingham for the degree of

Master of Research, 2020

School of Biosciences
University of Nottingham Malaysia

Abstract

Probiotics are defined as living microorganisms that when consumed in adequate amounts will exhibit health benefits to the host. Probiotics are known to play important roles in relief of lactose intolerance symptoms and improving gut health. However, till today the beneficial effect of probiotic bacterium is strain-specific, no single probiotic is able to resolve all gut health issues. Hence, the search for a stronger and more potent of probiotic bacterium is essential. Hence, the current study is aimed to isolate putative lactic acid bacteria from local fermented foods, namely *tempeh* and *tapai ubi*, and investigate the ability of these LABs to tolerate the upper gastrointestinal transit in an *in vitro* setting prior to future use as probiotics.

A total of 18 putative LABs were isolated from *tempeh* and *tapai ubi* using spread plate method with MRS selective medium. However only four isolates remained viable after frozen storage and was proceeded for subsequent studies. Three of the putative LABs were isolated from *tapai ubi* and designated as SU1, SU2, and SU8, and the putative LAB isolated from *tempeh* was designated as ST4. The identity of these four putative isolates were determined using 16s rRNA gene sequence analysis. SU1 and SU2 were identified as *Pediococcus acidilactici* with 80% and 87% similarity. SU8 was identified as *Pediococcus claussenii* with 82% similarity while ST4 was identified as *Leuconostoc mesenteroides* subsp. *mesenteroides* with 88% similarity.

After identification, the ability of these putative LAB isolates to survive the bile, gastric and small intestinal transits were evaluated in an *in vitro* setting. SU8, SU1

and SU2 were able to tolerate 0.5% of bile salt condition with growth ranging from 5.70 to 7.13 Log_{10}CFU/ml after 24h of incubation, except for ST4. ST4 was susceptible to 0.5 and 1.0% of bile salt. These putative LAB isolates were highly tolerant to the simulated gastric transit ranging from pH 2 to 4 and maintained a growth of more than 12 Log_{10}CFU/ml after 180 min of incubation. All four putative LAB isolates were able to tolerate the simulated small intestinal transit with addition of 0.3% bile salt and maintained a growth of more than 9 Log_{10}CFU/ml after 240 min of incubation. ST4 had the highest tolerance to the simulated small intestinal transit and therefore exhibited a putative potential as probiotics. Future study will need to be conducted to understand the health benefits exhibited by these putative LAB isolates for application as probiotics.

Table of contents

Abstract

Chapter 1: Introduction...1

1.1 Background of the study...1

1.2 Aim and Specific Objectives..3

Chapter 2: Literature Review...4

2.1 Origin of Probiotics...4

2.1.1 History and definition of probiotic...4

2.1.2 Source of probiotics...5

2.2 Lactic acid bacteria as probiotic...7

2.2.1 Probiotic characteristics of LAB...9

2.2.1.1 Acid and bile salt tolerance..9

2.2.1.2 Cell viability..10

2.2.1.3 High antibacterial and antimicrobial activity.................................11

2.2.1.4 Adhesion ability..11

2.2.1.5 Immune response enhancement...12

2.2.1.6 Cholesterol removal ability…………………………………………………………….12

2.2.1.7 Thermotolerance………………………………………………………………………….13

2.2.2 Health benefits of probiotics LAB…………………………………………………….14

2.2.2.1 Diarrhea treatment and prevention……………………………………………..15

2.2.2.2 Inflammatory Bowel Syndrome disease and treatment……………..16

2.2.2.3 Colon Cancer prevention……………………………………………………………..17

2.2.2.4 Hepatic disease…………………………………………………………………………….18

2.2.2.5 Hypertension………………………………………………………………………………..19

Chapter 3: Methodology…………………………………………………………………………..21

3.1 Isolation of putative lactic acid bacteria (LAB) from Malaysian fermented foods…….21

3.2 Maintenance of bacteria culture………………………………………………………22

3.3 Total viable plate count of bacteria…………………………………………………22

3.4 Identification of the putative LAB via 16s rRNA sequence analysis………………………………………………………………………………………………………23

3.4.1 Extraction of DNA………………………………………………………………………….23

3.4.2 Polymerase chain reaction……………………………………………………………………….24

3.4.3 16S rRNA gene sequence analysis………………………………………………………..26

3.5 Determination of the probiotic properties of the selected putative LAB………27

3.5.1 Bile tolerance assay…………………………………………………………………………….27

3.5.2 Simulated gastric and small intestinal transit tolerance assays………..27

3.5.2.1 Preparation of washed cell suspension…………………………………………….27

3.5.2.2 Preparation of simulated gastric juice………………………………………………27

3.5.2.3 *In vitro* gastric intestinal transit tolerance assay…………………………….28

3.5.2.4 Preparation of simulated small intestinal juice………………………………..28

3.5.2.5 *In vitro* small intestinal transit tolerance assay……………………………….28

3.6 Statistical analysis………………………………………………………………………………….29

Chapter 4: Results……………………………………………………………………………………….30

4.1 Isolation of putative lactic acid bacteria from Malaysian fermented foods…….30

4.2 Identification of the selected putative lactic acid bacteria via 16s rRNA sequence analysis…………………………………………………………………………………….32

4.3 Determination of *in vitro* bile tolerance of selected putative lactic acid bacteria..........38

4.4 Determination of the *in vitro* gastric intestinal transit tolerance of selected putative lactic acid bacteria..........40

4.4.1 Comparison of the tolerance of each putative LAB isolate when incubated in simulated gastric juice..........40

4.5 Determination of the *in vitro* small intestinal transit tolerance of selected putative lactic acid bacteria..........45

4.5.1 Comparison of the tolerance of each LAB isolate when incubated in simulated small intestinal juices..........45

Chapter 5: Discussion..........50

5.1 Isolation of putative lactic acid bacteria from fermented foods..........50

5.2 Identification of putative lactic acid bacteria..........51

5.3 Bile tolerance of selected putative lactic acid bacteria..........53

5.4 *In vitro* gastric transit tolerance of selected putative lactic acid bacteria....55

5.5 *In vitro* small intestine transit tolerance of putative lactic acid bacteria......56

Chapter 6: Conclusion and future recommendation..........58

References…………………………………………………………………………………………………..60

List of Figures

Figure 4.1: Phylogenetic tree of SU1…………………………………………………………………34

Figure 4.2: Phylogenetic tree of SU2…………………………………………………………………35

Figure 4.3: Phylogenetic tree of SU8…………………………………………………………………36

Figure 4.4: Phylogenetic tree of ST4………………………………………………………………..37

List of Tables

Table 3.1: Preparation of master mix for PCR………………………………………………….26

Table 4.1: Cell morphology of the putative lactic acid bacteria isolated from local fermented foods……………………………………………………………………………………………31

Table 4.2: Identities of isolate putative LABs via 16S rRNA gene sequence…….33

Table 4.3: Effect of bile salt concentration on growth of putative LAB isolates…39

Table 4.4: Comparison of the tolerance of SU1 when incubated in stimulated gastric juices adjusted to different pH……………………………………………………………….41

Table 4.5: Comparison of the tolerance of SU2 when incubated in stimulated gastric juice adjusted to different pH………………………………………………………………..42

Table 4.6: Comparison of the tolerance of SU8 when incubated in simulated gastric juices adjusted to different pH………………………………………………………………43

Table 4.7: Comparison of the tolerance of ST4 when incubated in simulated

gastric juices adjusted to different pH……………………………………………………………..44

Table 4.8: Effect of simulated small intestinal juices on the growth of SU1……46

Table 4.9: Effect of simulated small intestinal juices on the growth of SU2……47

Table 4.10: Effect of simulated small intestinal juices on the growth of SU8….48

Table 4.11: Effect of simulated small intestinal juices on the growth of ST4….49

Abbreviations

Common abbreviations

ANOVA	One-way analysis of variance
B.	*Bifidobacterium*
DMRT	Duncan multiple range test
DNA	Deoxyribonucleic acid
DNTP	deoxynucleotide triphosphates
E.	*Enterococcus*
EDTA	Ethylenediamine tetra-acetic acid
HCl	Hydrochloric acid
HE	Hepatic encephalopathy
IBS	Inflammatory Bowel Syndrome
L.	*Lactobacillus*
LAB	Lactic acid bacteria
Leu.	*Leuconostoc*
MHE	Minimal hepatic encephalopathy
MRS	De Man, Rogosa and Sharpe
NaOH	Sodium hydroxide

P.	*Pediococcus*
PCR	Polymerase chain reaction
RNase	Ribonuclease
rRNA	Ribosomal ribonucleic acid
Sacc.	*Saccharomyces*
spp.	*species pluralis*
subsp.	*Subspecies*

Units

%	percentage
°C	Degree Celsius
µl	Microliter
CFU/ml	Colony-forming unit per mL
G	gram
h	hour
M	Molar
m/v	Mass/volume
mg/ml	Milligram/milliliter
min	minute

ml	Milliliter
mM	Millimolar
s	second
U	micromol per minute
v/v	Volume/volume

Chapter 1 Introduction

1.1 Background of the study

Probiotics are living microorganisms, which when consumed in adequate amounts, will exhibit potential health benefit to the host (WHO, 2001). According to Food and Agriculture Organization (FAO) and World Health Organization (WHO), probiotics are living microorganism that play an important role in the digestive, immunological, and respiratory systems. Besides these, it may have positive effects towards alleviation of infectious diseases (FAO/WHO, 2006). Other than these health benefits, probiotics also play an important role in lowering the total cholesterol in the body, thus, reducing the risk of getting coronary heart disease (Miremadi, 2014; Chen, 2011).

Probiotics are mostly manufactured into probiotic drinks and the world-wide consumption of probiotic drinks have increased significantly throughout the year. According to Market Research Report (2020), the global probiotic drinks market has projected a significant growth rate of 8.44% from 2019 to 2024 with a market value of USD 45.3 billion by the end of the 2024. While the Yakult Honsha Co., Ltd. (2018) reported that the statistic of sales volume of probiotic drinks world-wide has increased significantly from 32,366 to 39,517 (thousands of bottles/day) from 2014 to 2018. Probiotic drinks market has the highest growth rate in Asia-Pacific during the forecast period due to the immense popularity of functional food and beverages of probiotics (Market Research Report, 2020).

According to Yakult Honsha Co., Ltd. (2018), the Asia region has the highest sale of yakult probiotic drinks compared to other countries. In Malaysia, probiotic supplements with *Lactobacillus* and *Bifidobacterium* were the most popular supplements in 2014 with the strongest annual growth rate of 15.4% among all supplements (Yap & Wan Nawawi, 2016).

Other than these commercial probiotic drinks and supplements, natural food products fermented by lactic acid bacteria (LAB) such as yogurt, kefir, kimchi and kombucha have been used as probiotics for their proposed health promoting properties. Several researchers have successfully isolated different types of LAB from Malaysian fermented food such as *tempoyak*, *tempeh*, *tapai ubi* (Khalil *et al*., 2018 Pisol *et al.*, 2015; Ramasamy *et al.*, 2012). *Tempeh* and *t*apai *u*bi were chose in this study for isolation of LAB because they are popular in Malaysia and other asia countries such as Indonesia and Philippines. Besides that, they rich in nutrients, tasty and affordable for everyone (Steinkraus, 2004; Babu *et al*., 2009).

In recent years, selected probiotic LAB strains have been thoroughly investigated for specific health effects such as *Lactobacillus rhamnosus GG, Lactobacillus acidophilus,* and *Bifidobacterium bifidum* (Ouwehand *et al*., 2002; de Roos & Katan, 2000). Properties like relief of lactose intolerance symptoms and shortening of rotavirus diarrhea by one or two days are now widely accepted as the health benefit for selected probiotic LABs (Crawford *et al*., 2017). Some areas, such as the treatment and prevention of atopy by probiotic LABs hold great promise. However, many proposed health effects still need additional investigation (Ouwehand

et al., 2002). Till today there is no single probiotic bacterium which able to resolve all the related health issues. Hence, this challenge has driven scientists and the author to continue to search for a stronger and more potent probiotic bacterium.

1.2 Aim and Specific Objectives

In the search of putative probiotics, the first step is to ensure that the probiotics are able to tolerate the gastrointestinal transit and remained viable when it reaches the small intestinal tract and colon to exert beneficial effects to the host. Hence, the current study is aimed to isolate putative lactic acid bacteria and investigate the probiotic potential of LAB isolated from local fermented foods, namely *tempeh* and *tapai ubi*, and investigate the ability of these LABs to tolerate the upper gastrointestinal transit in an *in vitro* setting.

The specific objectives were:

i) To isolate the putative probiotic lactic acid bacteria from local fermented foods.

ii) To identify the selected putative lactic acid bacteria using 16s rRNA sequence analysis.

iii) To investigate the simulated gastric transit tolerance of the selected putative lactic acid bacteria.

iv) To investigate the simulated small intestinal transit tolerance of the selected putative lactic acid bacteria.

Chapter 2 Literature review

2.1 Origin of Probiotics

2.1.1 History and definition of probiotics

Probiotics was originally described as 'substances produced by one protozoan which stimulated another' (Lily & Stillwell, 1965). Later on, it was described as 'an animal feed supplements which exert beneficial effect on the host animal by affecting the gut flora' (Parker, 1974). Then, the definition has revised by Fuller (1989) as 'a live microbial feed supplement which beneficially affects the host animal by improving the intestinal microbial balance'.

The history of probiotics started with fermented milks, that treated as medicine for body ailments that has been mentioned in Biblical scriptures in the early ages. According to Oberman (1985), Hippocrates prescribed sour milks as treatment for disorders of stomach and intestines. Then, in the beginning of the 20th century, the Russian bacteriologist Eli Metchnikoff (Pasteur Institute, France) was the first that gave a scientific explanation on the beneficial effects of lactic acid bacteria that present in fermented milk (Hughes & Hoover, 1991; O'Sullivan *et al*., 1992). In 1908, he implemented his 'longevity-without-aging' theory that explained that lactic acid caused the displacement of toxin producing that present in the intestine and resulting in prolonged lifespan (Lourens-Hattingh *et al*., 2001). Furthermore, Metchnikoff also proved that the growth and toxicity of anaerobic spore-forming bacteria was inhibited in large intestine after consuming products produced by lactic acid bacteria in sour milks (Lourens-Hattingh *et al*., 2001).

In 1920 to 1921, Rettger and his colleagues at Yale had shown the *Bulgarian bacillus* could not survive in the human gut and they used *L. acidophilus* instead (Rettger & Cheplin, 1921). This clinical trial gave good results in the patients with chronic constipation (Rettger *et al*., 1935).The interest of gut flora was raised in the second world war due to two factors: (a) the discovery of antibiotic growth promotion on animals that attempts to define the composition of the gut microflora through research; and (b) the improved techniques for raising germ-free animals (Fuller, 1992).

There were many studies about gut microflora and the used of lactic acid bacteria in food and the interest of probiotics continued. More recent studies have focused on the health benefits of the bacteria to the host and the survivability of the bacteria in the gastrointestinal tract (Lourens-Hattingh & Vijoen, 2001). This led to the changes and improvement for definition of probiotics. The most recent definition of probiotics was by The World Health Organization (2001) and defined as "living microorganisms which when apply in adequate amounts of health benefit on the host".

2.1.2 Source of probiotics

Probiotics are commonly found in fermented food and beverages such as milk, yogurt and cheese. The role of probiotics bacteria assists in milk is for preservation of the milk by generating lactic acid. As for yogurt and cheese, probiotics produced flavor compounds such as acetaldehyde, extracellular polysaccharides and other metabolites with organoleptic properties to the consumer (Parvez *et al*., 2006). The most common lactic acid bacterial use in world-wide are *Lactobacillus* and

Bifidobacteria (Chick *et al*., 2001; Van Hoorde *et al*., 2008; Ren *et al*., 2018).

Malaysia local fermented food such as *tempeh* and *tapai ubi* also contains probiotics. LABs that are usually found in *Tempeh are L. plantarum, Lactobacillus fermentum, Lactobacillus reuteri* and *Lactococcus lactis* (Feng *et al*., 2005; Huang *et al*., 2018). *Tempeh* is a soybean fermented product that is originally made by Central Javanese people through fermentation with *Rhizopus* species of fungi in the 1700s and is a world-wide accepted fermented product (Astuti *et al*., 2000). The production of *tempeh* was made by soaking and cooking to soften it and it taste mushroom or nutty odour. *Tempeh* can be fermented by different types of microorganism including moulds, yeasts, lactic acid bacteria and different species of gram-negative bacteria (Babu *et al*., 2009). Besides these, *Tempeh* provided staple diet to the consumers due to it being rich in protein, calcium, fibers, essential fatty acids and vitamin B-12 (Liem *et al*., 1977; Babu *et al*., 2009). *Tempeh* is consumed by a large population of consumers in Indonesia, Malaysia and other poor masses of countries as a source of proteins and calories, because it is a low-cost nutritious food is that affordable by all socio-economical groups (Babu *et al*., 2009).

Apart from *tempeh*, *tapai ubi* is another traditional fermented foods is that fermented using *Ragi* from Cassava (Djien, 1972). *Ragi* is a mixed culture of microorganisms used as a starter culture for *tapai ubi* fermentation (Djien, 1972). The production of the starter was by combining three groups of microorganisms such as mucoraceous fungi, yeasts and bacteria in the fermentation process (Hesseltine *et al*, 1988). The formation of *ragi* is always in the form of dry product, either as a

small flattened cake, a ball shape or as a white dusty powder (Hesseltine *et al*., 1988). As stated by Gandjar (2003), a well-prepared substrate and *ragi* will produce a good *tapai*. LABs that usually found in tapai ubi are *Lactobacillus brevis, L. plantarum, L. collinoides and Pediococcus* and *Enterobacteriaceae* (Chiang *et al*., 2006). After the fermentation, the flavor of tapai ubi is sweet, soft and juicy yet slightly alcoholic with a pleasant of aroma (Steinkraus, 2004). *Tapai ubi* is popular in Malaysia because it provided protein, thiamine content and folic acid to the consumer as dessert (Nor *et al*., 2008; Steinkraus, 2004).

2.2 Lactic acid bacteria as probiotics

The definition of 'fermentation' comes from a Latin word *fermentum* and it means boiling (Gogineni *et al*., 2013). The name originated by an observation of mixtures of crushed grapes that are kept in large vessels and produced bubbles while boiling. In ancient times, fermentation was used as preservation of food but the process of fermentation was carried out without any knowledge of microbial mechanisms (Chojnacka, 2010). Fermentation was established from ancient times in Egypt and the Middle East (McGovern, 2009). In 6,000 B.C., the earliest record of fermentation was in the Fertile Crescent region of lower Mesopotamia in between the Tigris and Euphrates rivers (Kiple & Ornelas, 2000). Then in 7,000 B.C, traditional Egyptian started to ferment milk products, Laban Rayeb and Laban Khad (Kosikowski & Mistry, 1997). Fast forward to 1941, the fermentation was introduced as using large scale of microorganism to produce product such as antibiotics, germ warfare, and lead to a huge increased of interested on microorganisms (Chojnacka, 2010).

In the year of 1980s, genetic engineering techniques was established to produce insulin (Chojnacka, 2010). The process of fermentation has been improving years by years. Nowadays, lactic acid fermentation was introduced and has been focused in word-wide especially in developing countries (Chelule *et al*., 2010). Most of the people preferred fermented food over unfermented food because of the longer preservation, texture and the colour of the food (Adriye & Laleye, 2003; Mosha & Vicent, 2004; Nout & Sarkar, 1999).

Besides this, lactic acid fermentation provide health benefits to consumers such as improved the nutritional value and digestibility of foods (Nout, 2009; Obiri-Danso *et al*., 1997), detoxification of mycotoxin in food (Mokoena *et al*., 2005; Chelule *et al*., 2010; Schnürer & Magnusson, 2005; Gourama & Bullerman, 1995; Dalié *et al*., 2010; Zinedine *et al*., 2005; Mokoena *et al*., 2006) and so on. Thus, fermented food has significantly increased the popularity as one of the main dietary components for developing world (Chelule *et al*., 2010).

The most important requirements for LAB is that it is non-invasive to the host and is safe to consume. According to Donohue & Salminen (1996), the *in vitro* study that test whether LABs such as *Lactobacillius, Lactococcus, Leuconostoc* and more will adhere to human intestinal cell lines to degrade the protective intestinal mucus intestinal cells has proved that the result was negative to the potential of LAB invading intestinal cells and damage the protective intestinal mucus. Besides that, two adhesion studies have been conducted to test the invasive properties of LAB by using Caco-2 cells (Coconnier *et al*., 1992; Elo *et al*., 1991). The results shown that

there were no invasive properties for LAB in this test. Intestinal mucus degradation is also considered as a marker of toxicity. As stated by Ruseler-van Embden *et al*. (1995), the study showed that probiotic strains such as *Lactobacillus GG, Lactobacillus acidophilus and Bifidobacterium bifidum* were not involved in mucosal degradation.

Furthermore, some of the clinical studies and animal studies have proven that LAB had an absence in toxicity (Donohue *et al*., 1993; Ishihara *et al*., 1985; Momose, 1979). Probiotics have been consumed in large quantities in this modern world. There are many LABs found as probiotics (Kongo, 2013) such as *L. rhamnosus, L. paracasei, L. fermentum, Enterococcus faecium, E. durans, L. plantarum, L. casei subsp. shirota, L. casei subps. immunitas, L. acidophilus subps. johnsonii* (Verdenelli *et al*., 2009; Kilic & Karahan, 2010; Kongo, 2013; Curto *et al*., 2011) and so on.

2.2.1 Probiotic characteristics of LAB

In order to ascertain the probiotic characteristics of LAB, a list of criterions must be fulfilled by the LAB. First and foremost, determination of the probiotic LAB strains of its taxonomic classification must be done (Wedajo, 2015). This gives an indication of the origin, habitat and physiology of the LAB strains. According to Moreilli (2007), LAB related with the habitats that are rich in nutrients, such as food products and plant materials. Then, several test for selection of probiotic must be done.

2.2.1.1 Acid and bile salt tolerance

LAB strains must be able to survive under acidic and bile conditions in human

gastrointestinal tract (Termont *et al*., 2006). It has to be tolerant to the stomach acid as low as pH 1.5 and the intestine with 2% concentration of bile salt (Dawson, 1998). Bile plays an important role as a biological detergent to emulsify lipids in the duodenum and also provided a strong antimicrobial activity that able to clutter the structure of cell membrane and lead to DNA destruction (Patel *et al*., 2012; Ruiz *et al*., 2013). There were several studies proved that LAB strains such as *Lactobacillus* and *Bifidobacterium* had resistance to acid and bile salt (Timmerman *et al*., 2007; Matto *et al*., 2004). Other than Lactobacillus and Bifidobacterium, *Weissella cibaria* from fermented vegetable-based food able to survive at pH 3.0 and tolerance against 0.3% oxgall bile salt (Ahn *et al*., 2013; Kim *et al*., 2018).

2.1.2 Cell viability

Cell viability is one of the important scientific criteria to classify the bacteria as probiotic (Amagase, 2008; Degnan, 2008; Vinderola *et al*., 2011). It is to determine the survivability of the cells by measuring the population of cells that survive through cell proliferation or different experimental conditions exposure (Riss *et al*., 2011). According to Ross *et al*. (2005), cell viability has been used for monitoring the corporation of probiotic and food production as a routine. It is an important assay for probiotic strains selection because to determine the ability of withstand stresses such as temperature, osmotic, solvent stress and freeze-drying for their progression to final from by manufacturing (Bron *et al*., 2011; Davis, 2014). A study of viability

of probiotic in Argentinian Fresco Cheese by Vinderola *et al*. (2000) showed that *Bifidobacterial* and *L. acidophilus* have high cell viability and able to survive after 60 days of refrigerated storage.

2.2.1.3 High antibacterial and antimicrobial activity

Besides this, LAB showed that it has antimicrobial substances against pathogen by producing the compound such as *lactolin* by *L. plantarum*, *lactobacillin* and *lactobrevin* by *L. brevis*, *acidophilin* and *lactocidin* by *L. acidophilus* and so on (Fuller, 1992) that will inhibit the growth or kill the pathogen (Desai, 2008). According to Campana *et al*. (2017), *L. case*i and *l. rhamnosus* showed that they have high antibacterial activity and other strains have moderate activity against the pathogens. There were other studies that proved that LAB strains provided antimicrobial activity (Servin, 2004; Marianelli *et al*., 2010). Lactic acid bacteria also produced hydrogen peroxide, diacetyl and bacteriocin as antimicrobial substances and against the foodborne pathogen and spoilage bacteria (Desai, 2008). As stated by Dave & Shah (1997), bacteriocin from the bacterium of the yoghurt able to against probiotic bacteria.

2.2.1.4 Adhesion ability

The capability of LAB to adhere to the intestinal mucosa is considered one of the criterions for probiotic. The adhesion of bacterial to intestinal surfaces is by hydrophobic interaction, then followed by specific cell wall components adhesion (H-addaji *et al*., 2015; Monteagudo-Mera *et al*., 2019). According to Pan *et al*. (2006)

has reported that there was a correlation between hydrophobicity and adhesion. Thus, some lactic acid bacteria contained surface proteins such as cell wall-anchored proteinases to enhance the hydrophobicity and adhesion (Muñoz-Provencio *et al*., 2012; Zhang *et al.*, 2015; Radziwill-Bienkowska *et al.*, 2017). Besides this, the presence of mucus-binding proteins in lactic acid bacteria cell wall such as *Bifidobacterium* and *Lactobacillus* able to enhance the process of adhesion of bacteria to intestine (Motherway *et al*., 2011; Piepenbrink & Sundberg, 2016; Reunanen *et al*., 2012; Toh *et al*., 2013). According to Rinkinen *et al*. (2000), the study observed that porcine *Enterococcus faecium* SF 273 able to adhere *in vitro* to canine intestinal mucus.

2.2.1.5 Immune response enhancement

Lactic acid bacteria able to enhance the immune response to the host. According to Matsuzaki & Chin (2000), *L. casei Shirota* strain has been injected into the mice and showed that there was a significantly increased in natural killer cells activity of mesenteric node cells and enhanced the innate immune response. In addition, there was a controlled clinical study to measure the enhancement of immune system in the elderly by consuming *B. lactis*. HN019 and *L. rhamnosus* HN001, and the result was positive towards the enhancement (Arunachalam *et al*., 2000; Gill *et al*., 2001; Sheih *et al*., 2001).

2.2.1.6 Cholesterol removal ability

High level of cholesterol is associated with cardiovascular diseases (CVD) and causes mortality in worldwide (Tomaro-Duchesneau *et al*., 2014). Several studies

have proven that probiotic bacteria could yield the level of cholesterol and low-density lipoprotein (LDL) cholesterol (Tomaro-Duchesneau *et al*., 2014; Sanders, 2000). Other than these, there was a *in vivo* male hamster study by Chiu *et al*. (2006) have proven that *Lactobacillus* strains such as *Lactobacillus paracasei subsp. paracasei*, *Lactobacillus plantarum* and *Lactobacillus acidophilus* successfully reduced the level of cholesterol in the blood and in the liver. According to Liong & Shah (2005), *lactobacilli* strains such as *L. acidophilus* and *L.casei* able to secret bile salt hydrolase that catalyzes the glycine- or taurine-conjugated bile salt hydrolysis into amino acid and free bile salts. Free bile salt was less soluble than conjugated bile salt and resulted a lower absorption in intestinal lumen. Thus, the deconjugation of bile salt has increased the amount of new bile salt to replace those have removed in the enterohepatic circulation, hence, the serum of cholesterol level was reduced. Besides that, probiotics such as *L. acidophilus* and *Bifidobacterium* strains able to assimilate some of the cholesterol from the medium by incorporating cholesterol into cell membrane during cell growth. Therefore, cholesterol that bind to the bacterial cell membrane would prevent absorption from the intestine into the blood (Liong & Shah, 2005a; Liong & Shah, 2005b; Watson & Preedy, 2015; Lye *et al*., 2009).

2.2.1.7 Thermotolerance

Probiotic such as *Lactobacillus* and *Bacillus subtilis* able to tolerant at mammalian gastric environment and temperature at 30°C and 37°C (Kim *et al*., 2019). However, the tolerance rate of *Lactobacillus* was declined while the temperature increases from 60°C due to the damage of the protective matrix in the

microbial cell wall (Mandal *et al*., 2006). Whereas for *Bacillus subtilis,* it has high survivability towards high temperature because it able to synthesize heat shock proteins when temperature increases (Schumann, 2003).

2.2.2 Health benefits of probiotics LAB

Probiotic bacteria contributed on a range of beneficial health effects to the host. In preparation of fermented food, inclusion of LAB could improve the quality, digestibility and bioavailability of nutrients in the food product (Parvez *et al*., 2006). LAB is also well-known to release different kind of nutrients such as folate by *Lactobacillus spp.* and *Lactococci spp.* (LeBlanc *et al*. 2007), vitamin B12 by *lactobacillus* of *L. reuteri* strain (Taranto *et al*., 2003), riboflavin by *L. fermentum* (Jayashree *et al*., 2010) and vitamin K by *Lactococcus, Lactobacillus, Enterococcus, Leuconostoc* and *Steptococcus* (Cooke *et al*., 2006; O'connor *et al*., 2005). According to Patel *et al*. (2012) and Novik *et al*. (2007), species of *Lactobacillus, Lactococcus, Pediococcus* and *Bifidobacterium* associated with fermented food produced carbohydrate degrading enzymes such as glucosidases, amylases and xylanases. However, there were reports that showed not all the probiotic bacteria attribute clinical effects to the host (Andersson *et al*., 2001). Thus, several studies from *in vitro*, animal and human studies have to be conducted to claim that the health benefits from certain probiotics is effective to the host.

2.2.2.1 Diarrhea treatment and prevention

There are numerous types of LAB that provided beneficial effect to diarrhea, travellers' diarrhea and diarrhea disease in young children that is caused by rotaviruses (Saavedra *et al*., 1994; Vanderhoof 2000). This included *Lactobacillus GG, Lactobacillus reuteri, Sacc. Boulardii, Bifidobacteria spp.,* and others (Duffy *et al*., 1994; Gorbach, 2000; Guandalini *et al*., 2000; Levy, 2000; Saavedra, 2000; Kyne and Kelly, 2001; Marteau *et al*., 2001; Benchimol & Mack, 2004). These probiotics decreased the viral shedding by increasing the secretary IgA in the immunological mechanism (Parvez *et al*., 2006). According to Desimone (1984) and O'Sullivan *et al*. (1992), probiotics can compete with invading viruses or bacteria pathogens that bind on epithelial cells and this might show an infection prevention effect to the individual. There were several studies that proven diarrhea was treated and prevented. According to Beck & Necheles (1961), *L. acidophilus* was effective towards diarrhea in humans and in gnotobiotic chicks that were inhabited with the *E. coli* pathogen (Watkins & Miller, 1983; Watkins *et al*., 1982).

Besides this, there was a study which determined the results of feeding a placebo calcium carbonate that contain tyophylized bacteria such as *Streptococcus thermophilus, Streptococcus lactis, Lactobacillus acidophilus, Lactobacillus bulgaricus* to infant and children who were associated with *E. coli*-mediated diarrhea and *Salmonella* and *Shigella* dysenteries in Yugosavia as treatment (Pearce & Hamilton, 1974; Tomic-Karovic & Fanjek, 1962; Zychowicz *et al*., 1974). The placebo calcium carbonate treatment had successfully recovered 66% in both groups of children, and

then all cases of dysenteries were eliminated by consuming *acidophilus* milk in long-term. Other than *L. acidophilus*, *Streptococcus faecium* SF 68 has been successfully used to alleviate diarrhea in animals (Underdahl *et al*., 1982) and humans, and also as an enteritis treatment in adult. The result was positive in all enteritis patients by observing the changes of the stool to normal stage after being administrated with *Streptococcus faecium* (Camarri *et al*., 1981; Lewenstein *et al*., 1979; Bellomo *et al*., 1980; Fernandes *et al*., 1987).

2.2.2.2 Inflammatory Bowel Syndrome disease

Inflammatory Bowel Syndrome (IBS) usually happens due to lactose and sucrose consumption by providing a nutritional source for pathogenic microbial population (Lin, 2004). These symptoms of IBS such as abdominal pain, flatulence, and irregular bowel movements (Santosa *et al*., 2006) happened collaboratively with the increase of the intestinal microbial population (Saarela *et al*., 2002; Lin, 2004).

There are reports which stated that an imbalance of intestinal bacteria, overgrowth of entero-adhesive and entero-hemorrhagic *Escherichia coli* and low levels of *Bifidobacterium*, might initiate the inflammation of these diseases (Saarela *et al*., 2002; Sartor, 1995; Rath, 2003). Probiotics was expected to decrease the pathogenic bacteria growth by lowering gut pH, providing barrier enhancement to prevent the invasion of pathogen and stimulating nonspecific and specific immune responses (Hart *et al*., 2003). As stated by Resta-Lenert & Barrett (2003), an *in vitro* study proven that probiotics might reduce the adhesion and invasion of epithelial cells.

Probiotcs such as *B. breve, B. bifidum and L. acidophillus* provided a beneficial effect in maintaining remission to ulcerative colitis by taking fermented milk as a complement (Cashman & Shanahan, 2003; Kato *et al*., 2004). Furthermore, as stated by Halpern *et al*. (1996) from a randomized, double-blind, crossover study, consuming *L. acidophilus* resulted an improvement of IBS from patients. Another study by Gade & Thorn (1989) showed an improvement on IBS patients who suffered for an average of 7 years by receiving *Enterococcus faecium*.

2.2.2.3 Colon Cancer prevention

Consuming probiotics could down regulate the activity of bacteria that have been associated with intestinal or colon cancer (Spanhaak *et al*., 1998; Ouwehand *et al*., 2002). Colon cancer was caused by the mutation of abnormal genes that control cell division when exposed to chemicals, namely carcinogens (Parvez *et al*., 2006). Carcinogens can be generated by metabolic activity of microbes that live in the gastrointestinal system (Santosa *et al*., 2006), such as enzymatic activity with enzymes β-glucuronidase, β-glucosidase, nitroreductase and so on (Santosa *et al*., 2006; Fernandes *et al*., 1987; Goldin *et al*., 1980; Goldin & Gorbach, 1984).

According to Sinha (1979), the study observed the significant decrease in fecal β-glucuronidase by ingesting *L. acidophilus*. Besides *L. acidophilus*, administration of *Lactobacillus casei* Shirota and *Bifidobacterium brev* also decreased of the β-glucuronidase activity (De Preter *et al*., 2008). There were other human intervention studies that showed LAB strains influenced the activity of nitroreductase and β-glucuronidase (Goldin *et al*., 1992; Benno & Mitsuoka, 1992; Bouhnik *et al*., 1996).

Moreover, the short-chain fatty acids such as butyrate produced by probiotics (Baghurst *et al*., 1996) lower down the pH of the digestive tract and prevent colon cancer (Malhotra, 1977; Segal *et al*., 1995). According to Kanauchi *et al*. (1999), the study showed that probiotic such as *Bifidobacterium* and *Eubacterium* have increased the production of butyrate. There were several studies that have proven that butyrate prevented colon cancer (Peng *et al*., 2009; Elamin *et al*., 2013; Roy *et al*., 2009;).

In addition, consumption of probiotic such as *lactobacilli* prevented the risk of developing tumors by binding to the mutagenic compound (Motta *et al*., 1991; Lidbeck *et al*., 1992; Murch, 2001; Isolauri, 2004). According Aso & Akazen (1992) and Aso *et al*. (1995), consumption of *L. casei* daily had delayed the recurrence of bladder tumor. There was an animal model study with 1,2-dimethylhydrazine (DMH)-induced colon cancer and showed that *Lactobacillus rhamnosus GG* has significantly reduced the incidence of colon tumors (Goldin *et al*., 1996).

2.2.2.4 Hepatic disease

Hepatic encephalopathy (HE) is a life-threatening liver disease in individuals which involves impairment of cognitive function (Sharma & Singh, 2016). According to Zhang *et al*. (2013), patients with minimal hepatic encephalopathy (MHE) were found to have high number of *streptococci* which is associated to cognitive impairment. Besides this, a study by Bajaj (2014) showed that patients with poor cognition associated with HE was found to have higher number of pathogens such as *Alcaligenaceae* and *Porphyromonadaceae* families.

Providing probiotic as a treatment has improved the imbalance in gut microbiota by decreasing the number of pathogenic bacteria and helped to improve endotoxemia, HE and liver functions (Liu *et al*., 2004). According to Bajaj *et al*. (2008), the reversal rate of MHE was significant higher in probiotic groups compared with the groups without treatment. There were several studies that showed consuming probiotics have positive effects on patient who has MHE and HE (Ziada *et al*., 2013; Sharma *et al*. 2008; Mittal *et al*. 2011; Mouli *et al*., 2014). The probiotics that have beneficial effect on disrupting the pathogenesis of HE included *Streptococcus thermophilus, Bifidobacteria, L. acidophilus, L.plantarum, L.casei, L. delbrueckii bulgaricus,* and *E. faecum* (Cunningham-Rundles *et al*., 2000; De Santis *et al*., 2000; Gorbach, 2000; Guslandi *et al*., 2000; Shanahan, 2001; Solga, 2003).

2.2.2.5 Hypertension

Probiotic bacteria play an important role in hypertension prevention. The development of hypertension was caused by inflammatory of endothelial dysfunction associated with the increased of systemic vascular resistance, commonly knowns as impaired endothelium dependent vasodilation due to imbalance between vasoconstrictors and vasodilators (Gomez-Guzman *et al*., 2015; Dinh *et al*., 2014). Consumption of probiotics inhibited the production of proinflammatory cytokines that will lead to the onset of hypertension (Matsuzaki *et al*., 2007; Arribas *et al*., 2008; Arribas *et al*., 2012). According to Gomez-Guzman *et al*. (2015), the study of probiotics treatment on hypertensive rats with *Lactobacillus fermentum* CECT5716 and *L. coryniformis* plus *L. gasseri* has improved the endothelial dysfunction and

resulted with reduction of vascular pro-inflammatory and pro-oxidative status. Besides this, a 3-weeks randomized, double-blind, placebo-controlled, parallel pilot study by Sharafedtinov *et al*. (2013) showed that subjects who consumed cheese with probiotics *Lactobacillus plantarum* have reduced blood pressure value compared to the control. According to Hata *et al* (1996), elderly patients who suffer with hypertension has consumed fermented milk with *Lactobacillus helyeticus* and *S. cerevisiae* experienced systolic and diastolic blood pressure reduction. Other than fermented milk, consuming powdered probiotic cell extracts also can lower the pressure of systolic and diastolic and heart rate (Sawada *et al*., 1990; Nakamura *et al*., 1995).

Chapter 3 Methodology

3.1 Isolation of putative lactic acid bacteria (LAB) from Malaysian fermented foods

Malaysian fermented foods such as fermented soybean curd *Tempeh* and fermented tapioca *Tapai Ubi* used in this study were purchased from the market and Tesco Cheras in Malaysia. Sample for each fermented foods was measured in 10g then put into a sterilized bag. After that, 90ml of sterile peptone buffered water was added into the sample and homogenized for 1 hour at room temperature. Then, 10-fold serial dilution (10^{-1} till 10^{-9}) was carried out by using peptone buffered water, in which 100 µl sample mixture (10^{0}) was pipetted into a sterilized Eppendorf tube that contained 900 µl of peptone buffered water. The 10^{-1} diluted sample was then mixed well by using vortex for 5s.

The steps above were repeated till obtained 10^{-9} diluted sample mixture. After that, 100 µl of each diluted sample was pipetted on MRS agar (de Man, Rogosa and Sharpe,1960) plate and spread well with sterile spreader. The agar plates were then incubated at 37°C for 48 hours. After incubation, 5 colonies on each food samples were picked and then inoculated into a sterile 10ml MRS broth, at 37°C for 24 hours. After that the cell morphology of the LAB culture was determined using Gram staining test. All assays were carried out in triplicate.

3.2 Maintenance of bacteria culture

All lactic acid bacteria cultures were subcultured twice and maintained in MRS broth and incubated at 37°C for 24 hours prior to assay. Bacteria cultures were stored in 20% (v/v) glycerol stock for long term storage. A total of 200 µl of sterile glycerol (100% v/v) was slowly pipetted into sterile Eppendorf tube. After that, 800 µl of revived culture was added into the Eppendorf tube that contained sterile glycerol, mixed well via vortex and stored in -20 or -80°C freezer.

3.3 Total viable plate count of bacteria

Total viable plate count was measured using Miles Misra method (Miles, Misra and Irwin, 1938) to quantify the number of bacteria present in a sample. A ten-fold serial dilution was carried out by pipetting 100 µl of active LAB culture into Eppendorf tube containing 900 µl of sterile peptone buffered water (dilution 10^{-1}). Then, this ten-fold serial dilution was repeated till dilution 10^{-9}. After that, 5 drops (10 µl /drop) of each diluted sample was pipetted onto MRS agar plate and allowed these drops to dissolve totally into the agar. All assays were conducted in triplicate. The agar plates were incubated at 37°C for 48 hours. The colonies formed were counted and the total viable plate count of bacteria present in a sample was determined using formula below:

$$\text{Total viable plate count (CFU/ml)} = \frac{\text{Number of colonies x Dilution factor (CFU)}}{\text{Sample volume plated (ml)}}$$

Notes: Dilution factor represent 10^1 to 10^9

3.4 Identification of the putative LAB via 16s rRNA sequence analysis

3.4.1 Extraction of DNA

In this step, Wizard Genomic DNA Purification Kit by 2020 Promega Corporation, USA was used. All the solutions were provided in the DNA purification kit.

1ml of a 24-h old putative LAB culture was added to a 1.5ml microcentrifuge tube. After that, the overnight culture was centrifuged at 13,000-16,000 x g for 2 minutes to pellet the cell, then the supernatant removed. The cells were resuspended thoroughly in 480 µl of 50mM EDTA. A total volume of 120 µl lysozyme buffer was added to the resuspended cell pellet, and gently pipetted to mix. The purpose of this pretreatment is to weaken the cell wall so that cell lysis can take place. Later on, the sample was incubated at 37°C for 30-60 minutes, then centrifuged for 2 minutes at 13,000-16,000 x g and the supernatant removed. Then, a total volume of 600 µl Nuclei Lysis solution was added and gently pipetted until the cells were resuspended. Afterwards, the mixture was incubated at 80°C for 5 minutes to lyse the cells, then cooled down at room temperature. A total volume of 3 µl RNase Solution was added to the cell lysate and inverted the tube for 2-5 times to mix well. Again, the mixture was incubated at 37°C for 15-60 minutes, then cooled down at room temperature. Following this, 200 µl of Protein Precipitation Solution was added to the RNase-treated cell lysate and vortexed vigorously at high speed for 20 seconds to mix the Protein Precipitation Solution with the cell lysate. After that, the sample was incubated on ice for 5 minutes, and then centrifuged at 13,000-16,000 x g for 3

minutes. The supernatant that contained the DNA was transferred to a clean 1.5ml microcentrifuge tube that contained 600 µl of isopropanol at room temperature.

The supernatant that remained in the original tube that contained the protein pellet was neglected to avoid the contaminating the DNA solution with the precipitated protein. Furthermore, the supernatant that contained DNA was gently mixed by inversion until the thread-like strands of DNA form a visible mass, then centrifuged at 13,000-16,000 x g for 2 minutes. The supernatant was carefully poured off and the tube was drained on a clean absorbent paper. Then, a volume of 600 µl of room temperature 70% ethanol was added and the tube gently inverted for several times to wash the DNA pellet. The DNA pellet was centrifuged at 13,000-16,000 x g for 2 minutes and then the ethanol was carefully aspirated. The tube was drained on a clean absorbent paper again and the pellet was allowed to air-dry in a biosafety cabinet for 10-15 minutes. Last but not least, 30 µl of DNA rehydration Solution was added to the tube and rehydrated the DNA by incubating at 65°C for 1 hour. The solution was mixed by gently tapping the tube. Otherwise, the DNA was rehydrated by incubating the solution overnight at room temperature or at 4°C. The DNA was stored at 2-8°C.

3.4.2 Polymerase chain reaction

The extracted DNA was proceeded to amplification using Polymerase Chain Reaction (PCR). The universal primers used were the 27F forward primer: 5′-AGA GTT TGA TCM TGG CTC AG-3′ and 1492R reverse primer: 5′-GGT TAC CTT GTT ACG ACT T-3′ (AI *et al*., 2008). The PCR master mix for 6 reactions were prepared based

on Table 3.1 using the DreamTaq DNA polymerase kit (Thermo Fisher Scientific, USA). The reagents listed in the Table 3.1 were mixed in a sterile 1.5ml microcentrifuge tube. After mixing thoroughly, a total of 19 µl aliquot of the mix was poured into 200 µl of PCR tube. 1 µl of sample was added into each tube except for one tube which was added with 1 µl of distilled water to use it as the PCR no-template control. Then, the 200 µl PCR tubes were transferred into a thermal cycler (Bio-Rad Laboratories, Inc; USA): (i) Initial hot start activation or denaturation step at 95°C - 98°C for 5 minute; (ii) Denaturation step at 95°C for 20s and annealing at 60°C for 30s; (iii) Extension steps were performed at 72°C for 30 s; (iv) final extension at 72°C for 5 mins and (v) stored at 10°C till used. Lastly, 5 µl of the PCR products were analysed by 1.5% agarose gel electrophoresis stained with SYBR® safe DNA gel stain in 1X TBE buffer for 30 mins (Thermo Fisher Scientific, USA).

Table 3.1: Preparation of master mix for PCR

Reagent	Stock concentration	Final Concentration
DreamTaq Polymerase Buffer	10x	1x
DNTP Mix	2 mM	0.20 mM
Forward primer	10 mM	0.20 mM
Reverse primer	10 mM	0.20 mM
DreamTaq Polymerase	5 U/µl	1.5 U/µl
Magnesium Chloride	50 mM	3.5 mM
Sterile distilled water	0	0

3.4.3 16S rRNA gene sequence analysis

The PCR products for selected putative LAB isolates were contracted out to the Apical Scientific Sdn Bhd, Malaysia for 16s rRNA sequence analysis. Then, the sequences generated were aligned in the genetic sequences database at GenBank® (BLAST, National Center for Biotechnology Information) to verify the genus and species of the LAB isolates.

3.5 Determination of the probiotic properties of the selected putative LAB

3.5.1 Bile tolerance assay

In this assay, 200 µl of 24h-old putative LAB isolate ($1x10^8$ CFU/ml) was inoculated into 10ml MRS broth added with 0%, 0.3%, 0.5% and 1.0% (w/v) of bile salt. The putative LAB isolate was then incubated at 37°C for 24 hours and followed by determination of total viable count using Mile Misra Method. All tests were carried out in triplicate and MRS broth with 0% bile salt was used as control.

3.5.2 Simulated gastric and small intestinal transit tolerance assays.

3.5.2.1 Preparation of washed cell suspension

A total of 10ml of 24h-old putative LAB isolate (1x108 CFU/ml) was centrifuged at 8000xg for 10 minutes, at 4°C. Then, 10ml of 50mM K_2HPO_4, pH7 buffer was used to wash the cell pellet. The supernatant was discarded, and the cell pellet were reconstituted back to the volume of 10ml using the same buffer. The washed cell suspension was ready to use for gastric and small intestine transit assay.

3.5.2.2 Preparation of simulated gastric juice

A 0.3% (w/v) pepsin was mixed in sterile 0.5% (w/v) NaCl. After that, the mixture was adjusted to pH2, 3, 4 correspondingly with 5M of HCl or NaOH to make fresh simulated gastric juice.

3.5.2.3 *In vitro* gastric intestinal transit tolerance assay

The washed cell suspension with volume of 200 µl was inoculated into 0.3ml of NaCl (0.5% w/v) in a sterile microcentrifuge tube. After that, 1.0ml of simulated gastric juice with different pHs (pH 2, 3 and 4) were added into the mixture correspondingly. Further on, the mixtures were vortexed for 10s and incubated in 37°C water bath for 180 minutes. At intervals of 0, 60, 120, and 180 minutes of incubation, 100 µl of aliquot was withdrawn to determine the total viable count. All tests were conducted in triplicate.

3.5.2.4 Preparation of simulated small intestinal juice

Pancreatin (0.1% w/v) was suspended in sterile 0.5% (w/v) NaCl. The mixture was then added with and without 0.3% (w/v) bile salt. Then, the pH of the simulated small intestinal juices was adjusted to pH 8 by using 5M of NaOH.

3.5.2.5 *In vitro* small intestinal transit tolerance assay

The washed cell suspension (as in Section 3.5.2.1) with a volume of 200 µl was inoculated into 0.3ml of NaCl (0.5% w/v) in a sterile microcentrifuge tube. Then, 1.0ml of simulated small intestine juices (pH 8; with or without 0.3% w/v bile salt.) were added into the mixtures respectively. The mixtures were vortexed for 10s and incubated in 37°C water bath for 240 minutes. At interval of 0, 60, 120, 180, and 240 minutes of incubation, 100 µl of the aliquot were taken out to determine the total viable count. All tests were carried out in triplicate.

3.6 Statistical analysis

Data analysis was performed using IBM SPSS Statistics version 24.0 (SPSS Inc, Chicago, IL, USA). One-way analysis of variance (ANOVA) followed by Duncan multiple range test (DMRT) was performed to correlate the difference between individual variables in all experiments. A value of $P < 0.05$ was considered as being statistically significant. All assays were conducted in triplicate.

Chapter 4 Results

4.1 Isolation of putative lactic acid bacteria from Malaysian fermented foods

In this study, a total of 18 putative lactic acid bacteria (LAB) isolates were isolated from *Tempeh* and *Tapai Ubi*. Table 4.1 showed the cell morphology of each isolate determined via Gram stain test. All of the isolates were confirmed as Gram-positive coccus-shaped bacteria. Isolates from *Tempeh* were designated as ST1 till ST9, while isolates from *Tapai Ubi* were designated as SU1 till SU9. Although all 18 isolates were stored at -20 and -80°C freezer, but most of the isolates were failed to revive when subculture step was performed at 37°C for 24-48h. Only four isolates survived and remained active and viable throughout this project. Thus, these four putative isolates, namely ST4 from *Tempeh* and SU1, SU2 and SU8 from *Tapai Ub*i were selected from subsequent assays. Last but not least, several tests such as catalase activity test (Whittenbury, 1964), coagulase test (Zdolec et al., 2013) and more will perform in future to justify the property of lactic acid bacteria.

Table 4.1: Cell morphology of the putative lactic acid bacteria isolated from local fermented foods

LAB isolates	Fermented Foods	Gram stain reaction	Cell Shape	Designation
1	Tempeh	+	Coccus	ST1
2	Tempeh	+	Coccus	ST2
3	Tempeh	+	Coccus	ST3
4	**Tempeh**	**+**	**Coccus**	**ST4 #**
5	Tempeh	+	Coccus	ST5
6	Tempeh	+	Coccus	ST6
7	Tempeh	+	Coccus	ST7
8	Tempeh	+	Coccus	ST8
9	Tempeh	+	Coccus	ST9
10	**Tapai Ubi**	**+**	**Coccus**	**SU1 #**
11	**Tapai Ubi**	**+**	**Coccus**	**SU2 #**
12	Tapai Ubi	+	Coccus	SU3
13	Tapai Ubi	+	Coccus	SU4
14	Tapai Ubi	+	Coccus	SU5
15	Tapai Ubi	+	Coccus	SU6
16	Tapai Ubi	+	Coccus	SU7
17	**Tapai Ubi**	**+**	**Coccus**	**SU8 #**
18	Tapai Ubi	+	Coccus	SU9

Note: # This isolate was selected for subsequent assays.

4.2 Identification of the selected putative lactic acid bacteria via 16s rRNA sequence analysis

Table 4.2 showed the 16S rRNA sequence analysis of the putative LAB isolates of SU1, SU2, SU8 and ST4. SU1 and SU2 had 98.94% and 98.61% of similarity with *Pediococcus acidilactici* strain ZPA017. While, SU8 shared 85.58% of similarity with *Pediococcus claussenii* ATCC BAA-344, and ST4 shared 98.01% of similarity with *Leuconostoc mesenteroides subsp. Mesenteroides* ATCC8293. The sequences for these putative isolates were presented in Figure 4.1-4.4.

Table 4.2: Identities of putative isolate LABs via 16S rRNA gene sequence

LAB	Name	Query Cover	E value	Identity	Accession no.
SU1	*Pediococcus acidilactici,* strain ZPA017	80%	0	98.94%	NZ_CP015206.1
SU2	*Pediococcus acidilactici* strain ZPA017	87%	0	98.61%	NZ_CP015206.1
SU8	*Pediococcus claussenii* ATCC BAA-344	82%	0	85.58%	NC_016605.1
ST4	*Leuconostoc mesenteroides subsp. mesenteroides* ATCC 8293	88%	0	98.01%	NC_008531.1

Figure 4.1: Phylogenetic tree of SU1



Figure 4.2: Phylogenetic tree of SU2



Figure 4.3: Phylogenetic tree of SU8



Figure 4.4: Phylogenetic tree of ST4



4.3 Determination of *in vitro* bile tolerance of the selected lactic acid bacteria

Table 4.3 showed the *in vitro* bile tolerance of the four putative LAB isolates (SU1, SU2, SU8 and ST4). The viable cell count for SU1 has the highest number of cells at 11.73 Log_{10} CFU/ml before adding the bile salt. After adding with 0.3% of bile salt, the viable cell count decreased by 2.08-fold. There was no significant different between the addition of 0.3% and 0.5% of bile salt. As for SU2 and SU8, the viable cell count started to decrease by 1.68-fold and 1.31-fold after the addition of 0.3% of bile salt. Interestingly, there was a significant increase of viable cell count by 1.33-fold and 1.1-fold when added with 0.5% of bile salt. However, no viable cell count was detected for SU1, SU2 and SU8 when 1.0% of bile salt was added. For ST4, the viable cell decreased by 1.84-fold after adding 0.3% of bile salt but there was no viable cell count detected from 0.5% to 1.0% of bile salt. Overall, SU8 showed the strongest tolerance to bile salt with highest viable cell count of 7.13 Log_{10} CFU/ml remained after incubation with 0.5% of bile salt. Whereas, ST4 showed the weakest tolerance to bile salt and failed to grow when incubated with 0.5% and 1.0% of bile salt.

Table 4.3: Effect of bile salt concentration on growth of putative LAB isolates

LAB	Bile salt%(w/v)			
	Viable cell count (Log_{10}CFU/ml) of LAB at different bile salt concentration			
	0% Bile	0.3% Bile	0.5% Bile	1.0% Bile
SU1	11.73 ± 0.20^{c}	5.64 ± 0.30^{b}	5.70 ± 0.26^{b}	0.00 ± 0.00^{a}
SU2	8.46 ± 0.41^{d}	5.01 ± 0.39^{b}	6.70 ± 0.02^{c}	0.00 ± 0.00^{a}
SU8	8.50 ± 0.12^{d}	6.48 ± 0.33^{b}	7.13 ± 0.22^{c}	0.00 ± 0.00^{a}
ST4	11.50 ± 0.31^{c}	6.25 ± 0.10^{b}	0.00 ± 0.00^{a}	0.00 ± 0.00^{a}

Notes: Values are mean ± standard deviation, n=3

abcd within a row, values with different superscripts are significantly difference at $P<0.05$

4.4 Determination of the *in vitro* gastric intestinal transit tolerance of selected putative lactic acid bacteria

The simulated gastric juices were adjusted to pH 2, 3 and 4 respectively and each putative LAB isolate was incubated in the gastric juices and the viable cell count was measured at different time intervals (0, 60, 120, and 180 min) as shown in Table 4.4-4.7.

4.4.1 Comparison of the tolerance of each putative LAB isolate when incubated in simulated gastric juice.

Isolate SU1 was incubated in simulated gastric juices adjusted to pH 2-4 (Table 4.4). At pH2, the viable cell count decreased significantly after 1 hour of incubation from 12.21 to 10.97 Log_{10} CFU/ml. At 120 min, the viable cell counts were increased and there was no significant reduction and addition afterwards. As for pH3, there was a significant increase after 1 hour of incubation, however, there was no significant difference after 60 min incubation. Lastly for pH4, there was no significant addition nor reduction throughout the 3 hours incubation. Overall, isolate SU1 showed strong tolerance to gastric juices with no significant difference in viable cell count at 180 min when compared to the control at 0 min.

Table 4.4: Comparison of the tolerance of SU1 when incubated in stimulated gastric juices adjusted to different pH

Time (min)	Viable cell count (Log_{10}CFU/ml) of SU1 when incubated in pH adjusted gastric juices at different incubation time		
	pH2	pH3	pH4
0	12.21 ± 0.19^{b}	12.48 ± 0.16^{a}	12.49 ± 0.07^{a}
60	10.97 ± 1.36^{a}	12.76 ± 0.19^{b}	12.47 ± 0.24^{a}
120	12.26 ± 0.22^{b}	12.75 ± 0.13^{b}	12.60 ± 0.08^{a}
180	12.05 ± 0.02^{b}	12.56 ± $0.09^{a,b}$	12.59 ± 0.14^{a}

Notes: Values are mean ± standard deviation, n=3

ab within a column, values with different superscripts are significantly difference at $P<0.05$.

Isolate SU2 was incubated in simulated gastric juices adjusted to pH 2–4 (Table 4.5). At pH 2, the viable cell count started to decrease at 60 min but it was no significant difference compared to 0 min. However, there was a significant reduction of viable cell count at 120 min incubation, and also it was the least viable cell count (12.2 Log_{10} CFU/ml). Then, the viable cell count remained constant and no significant reduction nor addition of cells was observed. At pH3, there was an increase in viable cell count after 1hour of incubation but it was not significantly different.

However, at 180 min, the viable cell count increased significantly and also the highest amount of viable cell count was observed (12.60 Log_{10} CFU/ml). Lastly for pH4, there was a significant reduction of viable cell count after 1hour incubation from 12.86 Log_{10} CFU/ml to 12.68 Log_{10} CFU/ml, which also showed the highest amount of viable cell count to the lowest. After that, there was no significant addition or reduction at 120 min and 180 min of incubation. Overall, isolate SU2 showed strong tolerance to gastric juice adjusted to pH 4 with no significant difference in viable cell count at 180 min when compared to control at 0 min.

Table 4.5: Comparison of the tolerance of SU2 when incubated in stimulated gastric juice adjusted to different pH

Time (min)	Viable cell count (Log_{10}CFUml) of SU2 when incubated in pH adjusted gastric juices at different incubation time		
	pH2	pH3	pH4
0	12.42 ± 0.05^{c}	12.44 ± 0.02^{a}	12.86 ± 0.10^{b}
60	12.35 ± $0.15^{b,c}$	12.62 ± $0.24^{a,b}$	12.68 ± 0.09^{a}
120	12.20 ± 0.04^{a}	12.65 ± $0.10^{a,b}$	12.77 ± $0.06^{a,b}$
180	12.26 ± $0.09^{a,b}$	12.69 ± 0.07^{b}	12.74 ± $0.05^{a,b}$

Notes: Values are mean ± standard deviation, n=3

abc within a column, values with different superscripts are significantly difference at $P<0.05$.

Isolate SU8 was incubated in simulated gastric juices adjusted to pH 2–4 (Table 4.6). There was no significant different for viable cell counts at PH 2 and PH 3

throughout the 3hours incubation period. At PH 4, there was no significant reduction of viable cell counts after 1hour incubation, but after incubated another 1hour which is at 120 min, there was a significant reduction. At 180 min, there was a significant increase of viable cell count. Overall, isolate SU8 showed strong tolerance to gastric juices adjusted with pH 2 and 3 with no significant difference in viable cell count at 180 min when compared to control at 0 min.

Table 4.6: Comparison of the tolerance of SU8 when incubated in simulated gastric juices adjusted to different pH

Time (min)	Viable cell count (L_{og}10CFU/ml) of SU8 when incubated in pH adjusted gastric juices at different incubation time		
	pH2	pH3	pH4
0	12.35 ± 0.03^{a}	12.62 ± 0.12^{a}	12.76 ± 0.05^{c}
60	12.58 ± 0.14^{a}	12.53 ± 0.15^{a}	12.72 ± 0.09^{b,c}
120	12.55 ± 0.20^{a}	12.64 ± 0.10^{a}	12.39 ± 0.12^{a}
180	12.51 ± 0.13^{a}	12.64 ± 0.06^{a}	12.57 ± 0.12^{b}

Notes: Values are mean ± standard deviation, n=3

abc within a column, values with different superscripts are significantly difference at P<0.05.

Isolate ST4 was incubated in simulated gastric juices adjusted to pH 2–4 (Table 4.7). At PH2, there was a significant increase of viable cell count after 1hour incubation. After that, the amount of cells had decreased significantly but is not significantly different between the amount of cells at 0 min. Furthermore, there was

no significant reduction at 180 min of incubation. For PH 3, there was a significant increased of the viable cell count after 1 hour of incubation. However, there was no significant different of viable cell count from 120 min to 180 min. Lastly for PH 4, there was a significant reduction of viable cell after one hour incubation but there was no significant addition of viable cell for another one more hour incubation (120 min). However at 180 min, there was a significant decreased of viable cell count and also was the least amount of cells produced at PH 4 (12.64 Log10 CFU/ml). Overall, isolate ST4 showed strong tolerance to gastric juice adjusted to pH3 with significant increase in viable cell count when compare the growth at 180 min with control at 0 min.

Table 4.7: Comparison of the tolerance of ST4 when incubated in simulated gastric juices adjusted to different pH

Time (min)	Viable cell count (Log_{10}CFU/ml) of ST4 when incubated in pH adjusted gastric juices at different incubation time		
	pH2	pH3	pH4
0	12.31 ± 0.13[a]	12.34 ± 0.14[a]	12.78 ± 0.06[b]
60	12.61 ± 0.11[b]	12.62 ± 0.02[b]	12.61 ± 0.10[a]
120	12.34 ± 0.06[a]	12.54 ± 0.18[b]	12.71 ± 0.04[a,b]
180	12.28 ± 0.05[a]	12.54 ± 0.08[b]	12.64 ± 0.03[a]

Notes: Values are mean ± standard deviation, n=3

ab within a column, values with different superscripts are significantly difference at P<0.05.

4.5 Determination of the *in vitro* small intestinal transit tolerance of selected putative lactic acid bacteria

Each putative LAB isolate was incubated in the in the simulated small intestinal juice adjusted to pH 8 with and without addition of bile salt. The viable cell count was measured at different time intervals (0, 60, 120, 180 and 240 min) as shown in Table 4.8-4.11.

4.5.1 Comparison of the tolerance of each putative LAB isolate when incubated in simulated small intestinal juices

The addition of bile salt in the simulated small intestinal juice had impact on the viable cell count of SU1. The viable cell count was maintained for the first 60 min of incubation but then significantly decreased to 9.82 Log_{10} CFU/ml after 240 min of incubation. Interestingly an increment on viable cell count was also observed at 180 min of incubation then followed by a reduction at 240 min. However, when SU1 was incubated in small intestinal juice without addition of bile salt, the viable cell count was maintained for first 120 min with no reduction in growth, followed by 22.21% of reduction at 180 min and resulted with 8.30 Log_{10} CFU/ml at 240 min.

Table 4.8: Effect of simulated small intestinal juices on the growth of SU1

Time (min)	Viable cell count (Log_{10}CFU/ml) of SU1 at different incubation time	
	With bile salt	Without bile salt
0	10.27 ± 0.14^{c}	10.90 ± 0.16^{c}
60	$10.10 \pm 0.12^{b,c}$	10.53 ± 0.31^{c}
120	9.78 ± 0.21^{a}	10.67 ± 0.13^{c}
180	11.70 ± 0.32^{d}	9.77 ± 0.10^{b}
240	$9.82 \pm 0.17^{a,b}$	8.30 ± 0.50^{a}

Notes: Values are mean ± standard deviation, n=3

abcd within a column, values with different superscripts are significantly difference at $P<0.05$.

The addition of bile salt in the simulated small intestinal juice had no impact on the viable cell count of SU2. The viable cell count ranging from 11.40–12.00 Log_{10} CFU/ml was maintained throughout the 240 min of incubation. Interestingly when SU2 was incubated in small intestinal juice without addition of bile salt, the viable cell count was decreased significantly by 2.62% after 240 min of incubation.

Table 4.9 : Effect of simulated small intestinal juices on the growth of SU2

Time (min)	Viable cell count (Log_{10}CFU/ml) of SU2 at different incubation time	
	With bile salt	Without bile salt
0	11.98 ± 0.22^{a}	12.21 ± $0.11^{b,c}$
60	11.40 ± 0.36^{a}	12.08 ± 0.08^{b}
120	11.95 ± 0.50^{a}	12.31 ± 0.10^{c}
180	11.58 ± 0.40^{a}	12.10 ± 0.13^{b}
240	12.00 ± 0.34^{a}	11.89 ± 0.16^{a}

Notes: Values are mean ± standard deviation, n=3

abc within a column, values with different superscripts are significantly difference at $P<0.05$.

The addition of bile salt in the simulated small intestinal juice had impacted on the viable cell count of SU8. The viable cell count was maintained for the first 60 min of incubation but then significantly increased to 12.05 and 12.02 Log $_{10}$CFU/ml after 120 and 180 min of incubation, respectively. However, after 240 min of incubation, no significant difference was observed between the viable cell count at 0 and 240 min. However, when SU8 was incubated in small intestinal juice without addition of bile salt, the viable cell count was maintained for first 180 min with no reduction in growth, followed by 2.73% of growth reduction at 240 min. The tolerance of LAB isolates when incubated in simulated small intestinal juices were performed to 240 min because the transit time for small intestine was 4hours or more (Szarka & Camilleri, 2012).

Table 4.10: Effect of simulated small intestinal juices on the growth of SU8

Time (min)	Viable cell count (Log_{10}CFU/ml) of SU8 at different incubation time	
	With bile salt	Without bile salt
0	11.37 ± 0.34^{a}	12.01 ± $0.10^{b,c}$
60	11.53 ± 0.26^{a}	11.80 ± $0.16^{a,b}$
120	12.05 ± 0.13^{b}	12.03 ± $0.19^{b,c}$
180	12.02 ± 0.10^{b}	12.06 ± 0.20^{c}
240	11.73 ± $0.36^{a,b}$	11.73 ± 0.11^{a}

Notes: Values are mean ± standard deviation, n=3

abc within a column, values with different superscripts are significantly difference at P<0.05.

The addition of bile salt in the simulated small intestinal juice had no impact on the viable cell count of ST4. The viable cell count ranging from 12.33 – 12.51 Log_{10}CFU/ml was maintained throughout the 240 min of incubation. Interestingly when ST4 was incubated in small intestinal juice without addition of bile salt, the viable cell count was decreased significantly by 2.97% after 60 min of incubation and the growth was then maintained throughout the 240min of incubation.

Table 4.11: Effect of simulated small intestinal juices on the growth of ST4

Time (min)	Viable cell count (Log_{10}CFU/ml) of ST4 at different incubation time	
	With bile salt	Without bile salt
0	12.51 ± 0.20[a]	12.43 ± 0.12[b]
60	12.44 ± 0.10[a]	12.06 ± 0.35[a]
120	12.42 ± 0.14[a]	12.32 ± 0.11[a,b]
180	12.35 ± 0.27[a]	12.30 ± 0.09[a,b]
240	12.33 ± 0.14[a]	12.16 ± 0.10[a,b]

Notes: Values are mean ± standard deviation, n=3

ab within a column, values with different superscripts are significantly difference at P<0.05.

Chapter 5 Discussion

5.1 Isolation of putative lactic acid bacteria from fermented food

In this study, De Man, Rogosa and Sharpe (MRS) was used as a selective medium for isolation and cultivation of putative lactic acid bacteria (LAB) which is typically used to isolate species of *Lactobacillus, Streptococcus, Pediococcus* and *Leuconostoc*, from Malaysian fermented foods (Marshall, 1992). MRS medium was supplemented with nutrients which included peptone and beef extract that supplied carbon and nitrogen to lactic acid bacteria culture, yeast extract which provided vitamin D and dextrose from carbohydrate for energy source (Abbasiliasi *et al*., 2017). With the use of MRS medium, a total of eighteen of LAB were isolated from *Tempeh* and *Tapai Ubi*. All putative isolates showed positive Gram stain reaction and cells with coccus shaped.

These results suggested that the Gram-positive coccus shaped putative LABs isolated from *Tempeh* and *Tapai Ubi* could be from the genera of *Pediococcus* and *Leuconostoc.* This result was determined by DNA extraction, polymerase chain reaction (PCR) and 16S rRNA gene sequence analysis. There were several research reported that *Tempeh* and *Tapai Ubi* contained various type of putative LABs such as *Lactobacillus plantarum, Lactobacilli spp,* and *Lactococcus lactis* (Kormin *et al*., 2001; De Vuyst & Vandamme, 2012; Babu *et al*., 2009; Ooi, 2010; Loh *et al*., 2008).

The variation in the types of putative LAB obtained from *tempeh* and *tapai ubi* could be due to the changes of environment and fermentation conditions such as pH,

temperature, salinity or other relative ingredients which may affect the microbial population of fermented foods (Li *et al*., 2016; Giraffa, 2004). Unfortunately, in this study only four putative LAB isolates, namely SU1, SU2, SU8 from *Tapai Ubi* and ST4 from *Tempeh* remained viable after frozen storage, and hence these isolates were proceeded to subsequent assays.

5.2 Identification of putative lactic acid bacteria

According to Mora *et al*. (1997), the molecular identification of 16S rRNA sequence analysis is a powerful technique to determine the phylogenetic relationship of microorganism. Hence this analysis was adopted to identify the four putative LAB isolates (SU1, SU2, SU8 and ST4) from *Tempeh* and *Tapai Ubi*. In this analysis, SU1 and SU2 were identified as *Pediococcus acidilactici*, SU8 was identified as *Pediococcus claussenii*, and ST4 was identified as *Leuconostoc mesenteroides subsp. mesenteroides*. SU8 has only 85% of Pediococcus claussenii identity which is far lower than the cut-off for same genus (>94%), and also even much lower than the same species (<97%). Further verification on the identification will be done in future.

The genus of *Pediococcus* is the member of lactic acid bacteria family with characteristics such as coccus-shaped, gram-positive, non-mobile, non-spore formation, catalase-negative and anaerobic (Porto *et al*., 2017). There are seven *Pediococcus* species recognized which are P*. acidilactici, P. damnosus, Pediococcus inopinatus, P. parvulus, P. pentosaceus, Pediococcus urinaeequi* and *P. dextrinicus.* However, *P. dextrinicus* is considered a distantly related species compared to the others (Chaban *et al*., 2002). *Pediococcus* bacteria also produce pediocins which are

bacteriocins that have a wide range of bactericidal activity against the gram-positive bacteria and is used for food preservation (Biswas *et al*., 1991).

P. acidilactici and *P. claussenii* are usually used in beer fermentation but they can also be found in *Tapai Ub*i due to the low alcohol content in the fermentation process (Dobson *et al*., 2002). *P. acidilactici* is found in *Ragi*, a culture-mixed microorganism for *tapai* fermentation (Chiang *et al*., 2006). As for *P. claussenii*, it considered as a new species that is found in *Pediococcus* species by using phylogenic analysis (Chaban *et al*., 2002). Besides this, *P. claussenii* is commonly found in beer spoilage and it is known as a brewery contaminant (Pittet *et al*., 2012). It produces a slimy product, exopolysaccharide, which may be involved in forming biofilm in brewery. This bacterium contains the gene of *hor*A that is associated with spoilage; it causes the beer to spoil in 7 to 8 days (Haakensen *et al*., 2008).

Fermentation of *Tempeh* commonly uses the mould *Rhizopus oligosphorus* as the starter culture, but *Leuconostoc mesenteroides subsp. mesenteroides* bacteria also plays a huge part in this fermentation process (Pisol *et al*., 2015). It is a facultative anaerobic that is involved in a complex growth factor and amino acids. Besides this, it is immotile and its shape is cocci. According to Daba *et al*. (1991), *L. mesenteroids* has the ability to produce bacteriocin to against a well-known food-borne pathogen, *Listeria monocytogenes*.

5.3 Bile tolerance of selected putative lactic acid bacteria

Probiotics need to survive throughout the acid and bile conditions in the gastrointestinal tract in order to reach the small intestine and colon to provide health benefits to the host (Gibson *et al*., 2000). Bile salts are produced in the liver and made by bile acid that is conjugated with glycine or taurine (Bodewes *et al*., 2015). Bile salt is a toxic compound to bacteria. It is composed of lipids and fatty acid that interact with bacterial cell membranes to inhibit the growth and kill the bacteria. Besides this, bile salt is also involved in intracellular acidification which inhibits the proton motive force, as well as inhibit the transport of nutrients. Despite the toxicity of bile salt, some LABs produce bile salt hydrolase and is able to hydrolyze the bile salt and survive the harsh gut environment (Abbasiliasi *et al*., 2012).

Table 4.3 showed that the growth of the four putative LAB isolates reduced significantly after treatment with 0.3% of bile salt and was inhibited totally at 1.0% of bile salt. According to Liong & Shah (2005), their study showed that conjugated bile salt could inhibit *lactobacilli* strains. There was another study which showed that *Lactobacillus acidophilus* is able to survive under 1%, 2% and 3% of bile but the viable count decreased when the amount of bile increased (Pan *et al*., 2009). In addition, Shehata *et al*. (2016) and Jin *et al*. (1998) reported that some LABs such as *Lactobcoccus* and *Lactobacillus* were able to survive at 0.3% of bile salt for 3 hours of incubation.

In this study, the four putative LAB isolates were incubated for 24h and were still able to show tolerance to 0.3% of bile salt despite reduction in viable cell count

to a range of 5.01 – 6.48 Log_{10}CFU/mL. Several studies have proven that *Pediococcus* and *Leuconostoc* are able to tolerant below 0.3% of bile salt (Kobore *et al*., 2012; Sukumar & Ghosh, 2010; Zhang *et al*., 2013; Yi *et al*. 2017).

SU1, SU2 and SU8 continue to show tolerant 0.5% bile salt, except for ST4. All four putative isolates were susceptible to 1.0% bile. Current findings indicated that *P. claussenii* SU8, *P. acidilactici* SU1 and SU2 were able to tolerate 0.5% of bile salt condition, with SU8 showing the highest viability of 7.13 Log_{10}CFU/ml. Whereas, *L. mesenteroides sp. mesenteroides* ST4 was least tolerant to bile salt condition.

Similar observation was also reported by Sabir *et al*. (2010) where their study showed that *P. acidilactici* was able to survive at the concentration of 0.5% bile salt, but poor survival ability was recorded for *L. mesenteroides*. However, a contrasing study was reported by Mandal *et al*. (2009) where *P. acidilactici* was found to tolerant up to 2% of bile salt (20 mg/ml) after 24 hours overnight incubation. According to Surono (2003), *Leu. mesenteroides* had a poor survival rate in the presence of 0.3% of oxgall. In contrast, Benmechernene *et al*. (2013) and El-Jeni *et al*. (2016) reported that *L. mesenteroides* survived well with the concentration of 0.5%, 1% and 2% of bile salt for 4h incubation but the viability of the cells was reduced. Thus, these reports suggested that *L. mesenteroides* might be able to tolerate bile salt for 4 hours but not after 24 hours of incubation.

In this study, even though *Leu. mesenteroides* ST4 had poor survival rate at 0.5% of bile salt, it is possible that this isolate will still survive through the duodenum and proceed to the small intestinal tract because the human small intestinal tract

normally contain 0.3% of bile salt (Begley *et al*., 2006; Gilliland *et al*., 1984).

5.4 *In vitro* gastric transit tolerance of selected putative lactic acid bacteria

Human stomach produces gastric juice with a low pH between 2.5 to 3.5 (Holzapfel *et al*., 1998; Huang & Adams, 2004). The importance of testing gastric transit assay on probiotics is to understand the survivability of the probiotics in order to transmit the health benefit to the small intestine (Corcoran *et al*., 2005).

The current study showed that all four putative LAB isolates *P. claussenii* SU8, *P. acidilactici* SU1, SU2, and *Leu. mesenteroides* ST4 have high tolerance to the acidic environment in the stomach ranging from pH 2 to 4 and maintained a high viable cell count exceeding 12 Log_{10}CFU/ml. Similar findings were reported by other researches (Immerstand *et al*., 2010; Shukla *et al*., 2015; Seo *et al*., 2012).

According to Erkkilä & Petäjä (2000), *P. acidilactici* has the capacity of surviving under acidic condition from pH1 to 5 and 0.3% of bile salts. Guerra *et al*. (2007) also reported that, *P. acidilactici* was tolerant to pH 2,3,4 and 5 at the incubation of 4 hours. It also survived in the acidic condition slightly better than *Lactococcus lactis* and *Enterococcus faecium*. According to Immerstrand *et al*. (2010), *P. parvulus* survived a 4 hours exposure to the simulated gastric juice adjusted to pH 2.5 and pepsin at 37°C, but at pH 1.5, viability of the cell was reduced significantly.

Shukla *et al*. (2014) and Seo *et al*. (2012), reported that *L. mesenteroides* showed resistance to the simulated gastric juice at pH 3 and has a high survival rate. Zhang *et al*. (2013) and El-Jeni *et al*. (2016) showed that *L. lactis* and

L. mesenteroides were tolerant to pH 1.5 to 4.5.

5.5 *In vitro* small intestinal transit tolerance of putative lactic acid bacteria

The current study showed that all four putative LAB isolates *P. claussenii* SU8, *P. acidilactici* SU1, SU2, and *Leu. mesenteroides* ST4 have high tolerance to the alkaline environment in the small intestinal tract with the addition of 0.3% bile salt and maintained high viable cell count ranging from 9.82 to 12.33 Log_{10}CFU/ml after 240 min of incubation. Among the four putative isolates tested, ST4 showed the strongest tolerance and SU1 showed the lowest tolerance to the simulated small intestinal transit.

According to Prommadee *et al*. (2012), the study showed the *P. pentosaceus* was tolerant to the small intestinal condition which was pH8 with 0.3% of bile salt even though the viability was decreasing significantly within 4 hours. Besides this, there were several findings which proved that *Pediococcus* and *Leuconostoc* are tolerant to the small intestine condition (Kumar *et al*., 2020; Devi *et al*., 2015; Diana *et al*., 2015; Le & Yang, 2019).

In contrast, there was a finding by Tokatli *et al*. (2015) which showed that *P. ethanolidurans* strains were sensitive to simulated intestinal juice and gastric juice. In this study, ST4 had a better survivability under small intestine condition and thus showed the strongest tolerance in the small intestinal transit.

Surprisingly, when the bile salt was removed from the simulated small intestinal transit, SU1, SU2 and SU8 showed significant reduction of viable cell counts

ranging from 0.28 to 2.6 Log_{10}CFU/ml after 240 min of incubation. Only ST4 showed strong tolerance to the simulated small intestinal transit and with no significant different in viable cell count after 240 min of incubation. The underlying mechanism for this bile removal effect remains unknown and further study will need to be conducted.

Chapter 6 Conclusion and future recommendations

This study was conducted to search of putative probiotics from local fermented foods such as *Tempeh* and *Tapai Ubi*. A total of 18 putative LAB were isolated from *tempeh* and *tapai ubi* using MRS selective medium. However only four putative isolates remained viable after frozen storage. The putative LAB isolated from *Tapai Ubi* were designated as SU1, SU2, and SU8, and the putative LAB isolated from *Tempeh* was designated as ST4. The identity of these four putative isolates were determined using 16s rRNA gene sequence analysis. SU1 and SU2 were identified as *Pediococcus acidilactici*. SU8 was identified as *Pediococcus claussenii* and ST4 was identified as *Leuconostoc mesenteroides* subsp. *mesenteroides.* The ability of these four putative LABs to tolerate bile and gastric transit and remained viable when reaching the small intestinal tract of the host in an *in vitro* setting was determined. *P. claussenii* SU8, P*. acidilactici* SU1 and SU2 were able to tolerate 0.5% of bile salt condition, except for *L. mesenteroides* subsp. *mesenteroides* ST4. All four putative LABs were highly tolerant to the simulated gastric transit ranging from pH 2 to 4 and maintained a growth of more than 12 Log_{10}CFU/ml. All four putative LABs were able to tolerate the simulated small intestinal transit with addition of 0.3% bile salt. In conclusion, SU1, SU2 and SU8 have high tolerance to small intestinal transit and bile salt. However, ST4 was the least tolerant to bile salt as it cannot withstand more than 0.3% bile salt. This will be taking consideration on further investigation in future for more explanation.

In this study, the four putative LABs were isolated from Malaysian fermented food and all of them were able to tolerate the harsh gastrointestinal environments. In order to ascertain the probiotic potential of these four putative LABs, future *in vitro* and *in vivo* studies to evaluate the health benefits of putative LAB to the host will need to be conducted. *In vitro* studies such as determination of antimicrobial activity of the putative LAB in eliminating the pathogen in the host and maintain a balanced gut microflora; ability of putative LAB to assimilate cholesterol in serum; the mode of action of putative LAB to reduce gastrointestinal disease could be conducted. The putative LAB with significant health benefits could then proceed to in vivo animal trial to validate the probiotic potential.

Reference

Abbasiliasi, S., Tan, J.S., Bashokouh, F., Ibrahim, T.A.T., Mustafa, S., Vakhshiteh, F., Sivasamboo, S. and Ariff, A.B. (2017). *In vitro* assessment of *Pediococcus acidilactici* Kp10 for its potential use in the food industry. *BMC microbiology, 17*(1), p.121.

Abbasiliasi, S., Tan, J.S., Ibrahim, T.A.T., Ramanan, R.N., Vakhshiteh, F., Mustafa, S., Ling, T.C., Rahim, R.A. and Ariff, A.B. (2012). Isolation of *Pediococcus acidilactici* Kp10 with ability to secrete bacteriocin-like inhibitory substance from milk products for applications in food industry. *BMC microbiology, 12*(1), p.260.

Ahn, S.B., Park, H.E., Lee, S.M., Kim, S.Y., Shon, M.Y. and Lee, W.K. (2013). Characteristics and immuno-modulatory effects of *Weissella cibaria* JW15 isolated from Kimchi, Korea traditional fermented food, for probiotic use. *Journal of Biomedical Research, 14*(4), pp.206-211.

Alm, L. (1982). Effect of fermentation on lactose, glucose, and galactose content in milk and suitability of fermented milk products for lactose intolerant individuals. *Journal of Dairy Science, 65*(3), pp.346-352.

Amagase, H. (2008). Current marketplace for probiotics: a Japanese perspective. *Clinical infectious diseases, 46*(Supplement_2), pp.S73-S75.

Anandharaj, M., Sivasankari, B., Santhanakaruppu, R., Manimaran, M., Rani, R.P. and Sivakumar, S. (2015). Determining the probiotic potential of cholesterol-

reducing *Lactobacillus* and *Weissella* strains isolated from *gherkins* (fermented cucumber) and south Indian fermented *koozh*. *Research in microbiology, 166*(5), pp.428-439.

Andersson, H., Asp, N.G., Bruce, Å., Roos, S., Wadström, T. and Wold, A.E. (2001). Health effects of probiotics and prebiotics A literature review on human studies. Näringsforskning, 45(1), pp.58-75.

Arribas, B., Garrido-Mesa, N., Perán, L., Camuesco, D., Comalada, M., Bailón, E., Olivares, M., Xaus, J., Kruidenier, L., Sanderson, I.R. and Zarzuelo, A. (2012). The immunomodulatory properties of viable *Lactobacillus salivarius ssp. salivarius* CECT5713 are not restricted to the large intestine. *European journal of nutrition, 51*(3), pp.365-374.

Arribas, B., Rodríguez-Cabezas, M.E., Comalada, M., Bailón, E., Camuesco, D., Olivares, M., Xaus, J., Zarzuelo, A. and Gálvez, J. (2008). Evaluation of the preventative effects exerted by *Lactobacillus fermentum* in an experimental model of septic shock induced in mice. *British journal of nutrition, 101*(1), pp.51-58.

Arunachalam, K., Gill, H.S. and Chandra, R.K. (2000). Enhancement of natural immune function by dietary consumption of *Bifidobacterium lactis* (HN019). *European Journal of Clinical Nutrition, 54*(3), pp.263-267.

Aso, Y. and Akazan, H. (1992). Prophylactic effect of a *Lactobacillus casei* preparation on the recurrence of superficial bladder cancer. *Urologia internationalis, 49*(3),

pp.125-129.

Aso, Y., Akaza, H., Kotake, T., Tsukamoto, T., Imai, K., Naito, S. and BLP Study Group. (1995). Preventive effect of a *Lactobacillus casei* preparation on the recurrence of superficial bladder cancer in a double-blind trial. *European urology, 27,* pp.104-109.

Assets.fishersci.com. (2020). [online] Available at: https://assets.fishersci.com/TFS-Assets/LSG/manuals/egel_sybr_safe_qrc.pdf [Accessed 25 Feb. 2020].

Assets.thermofisher.com. (2020). *This protocol is for the Analysis of Thermo Scientific Recombinant Clones*. [online] Available at: https://assets.thermofisher.com/TFS-Assets/LSG/manuals/MAN0011924_Analysis_Recombinant_Clones_UG.pdf [Accessed 25 Feb. 2020].

Assets.thermofisher.com. (2020). *SYBR™ Safe DNA Gel Stain*. [online] Available at: https://assets.thermofisher.com/TFS-Assets/LSG/manuals/sybr_safe_dna_gel_stain_man.pdf [Accessed 7 Mar. 2020].

Astuti, M., Meliala, A., Dalais, F. and Wahlqvist, M. (2000). *Tempe*, a nutritious and healthy food from Indonesia. *Asia Pacific Journal of Clinical Nutrition*, 9(4), pp.322-325.

Babu, P.D., Bhakyaraj, R. and Vidhyalakshmi, R. (2009). *A low cost nutritious food "tempeh"-a review*. *World J Dairy Food Sci, 4*(1), pp.22-27.

Babu, P.D., Bhakyaraj, R. and Vidhyalakshmi, R. (2009). A low-cost nutritious food *tempeh*-a review. *World Journal of Dairy & Food Sciences, 4*(1), pp.22-27.

Baghurst, P.A., Baghurst, K.I. and Record, S.J. (1996). Dietary fibre, non-starch polysaccharides and resistant starch: a review. *Food Australia, 48*(3), pp.S3-S35.

Bajaj, J.S. (2014). The role of microbiota in hepatic encephalopathy. *Gut Microbes, 5*(3), pp.397-403.

Bajaj, J.S., Saeian, K., Christensen, K.M., Hafeezullah, M., Varma, R.R., Franco, J., Pleuss, J.A., Krakower, G., Hoffmann, R.G. and Binion, D.G. (2008). Probiotic yogurt for the treatment of minimal hepatic encephalopathy. *American Journal of Gastroenterology, 103*(7), pp.1707-1715

Beck, C. and Necheles, H. (1961). Beneficial effects of administration of *Lactobacillus acidophilus* in diarrheal and other intestinal disorders. *The American journal of gastroenterology, 35*, pp.522-530.

Begley, M., Hill, C. and Gahan, C.G. (2006). Bile salt hydrolase activity in probiotics. *Appl. Environ. Microbiol., 72*(3), pp.1729-1738.

Bellomo, G., Mangiali, A., Nicastro, L. and Frigerio, G. (1980). A controlled double-blind study of SF68 strain as a new biological preparation for the treatment of diarrhea in pediatrics. *Curr. Ther. Res. 28*, pp.927-936.

Benchimol, E.I. and Mack, D.R. (2004). Probiotics in relapsing and chronic diarrhea. *Journal of pediatric hematology/oncology, 26*(8), pp.515-517.

Benmechernene, Z., Chentouf, H.F., Yahia, B., Fatima, G., Quintela-Baluja, M., Calo-Mata, P. and Barros-Velázquez, J. (2013). Technological aptitude and applications of *Leuconostoc mesenteroides* bioactive strains isolated from Algerian raw camel milk. *BioMed research international, 2013.*

Benno, Y. and Mitsuoka, T. (1992). Impact of *Bifidobacterium longum* on human fecal microflora. *Microbiology and immunology, 36*(7), pp.683-694.

Bio-rad.com. (2020). *Overview of the Protocol AutoWriter*. [online] Available at: https://www.bio-rad.com/webroot/web/pdf/lsr/literature/10021377.pdf [Accessed 25 Feb. 2020].

Bio-rad.com. (2020). *Thermal Cyclers for PCR | Life Science Research | Bio-Rad*. [online] Available at: https://www.bio-rad.com/en-my/category/thermal-cyclers-for-pcr?gclid=CjwKCAiAu9vwBRAEEiwAzvjq-0jLFKipq-ksR4Q4IWPAg4uiJKbwA8PKZ1O69P-soYaZV9gfmP3OihoC6n4QAvD_BwE&WT.knsh_id=a49b0383-8a6c-4099-bff9-e232038404ff&WT.srch=1&ID=75f1b406-3746-4580-a998-74245b094f56&WT.mc_id=170125002295 [Accessed 7 Mar. 2020].

Biswas, S.R., Ray, P., Johnson, M.C. and Ray, B. (1991). Influence of growth conditions on the production of a bacteriocin, pediocin AcH, by *Pediococcus acidilactici*H. *Appl. Environ. Microbiol., 57*(4), pp.1265-1267.

Bodewes, F.A., Wouthuyzen-Bakker, M. and Verkade, H.J. (2015). Persistent Fat Malabsorption in Cystic Fibrosis. *In Diet and Exercise in Cystic Fibrosis*, pp. 373-381. Academic Press.

Bouhnik, Y., Flourie, B., Andrieux, C., Bisetti, N., Briet, F. and Rambaud, J.C. (1996). Effects of *Bifidobacterium sp* fermented milk ingested with or without inulin on colonic *bifidobacteria* and enzymatic activities in healthy humans. *European Journal of Clinical Nutrition, 50*(4), pp.269-273.

Bron, P.A., van Bokhorst-van de Veen, H., Wels, M. and Kleerebezem, M. (2011). Engineering robust lactic acid bacteria. *In Stress Responses of Lactic Acid Bacteria* (pp. 369-394). Springer, Boston, MA.

Camarri, E., Belvisi, A., Guidoni, G., Marini, G. and Frigerio, G. (1981). A double-blind comparison of two different treatments for acute enteritis in adults. *Chemotherapy, 27*(6), pp.466-470.

Campana, R., van Hemert, S. and Baffone, W. (2017). Strain-specific probiotic properties of lactic acid bacteria and their interference with human intestinal pathogens invasion. *Gut pathogens, 9*(1), p.12

Cashman, K.D. and Shanahan, F. (2003). Is nutrition an aetiological factor for inflammatory bowel disease?. *European journal of gastroenterology & hepatology, 15*(6), pp.607-613.

Chaban, B., Dobson, C.M., Whiting, M.S., Bjarnason, J. and Ziola, B. (2002). Immunoblotting used for identification of beer spoilage *pediococci*, including the new species *Pediococcus claussenii*. *Journal of the American Society of Brewing Chemists, 60*(4), pp.170-175.

Chelule, P.K., Mbongwa, H.P., Carries, S. and Gqaleni, N. (2010). Lactic acid fermentation improves the quality of *amahewu*, a traditional South African maize-based porridge. *Food Chemistry, 122*(3), pp.656-661.

Chelule, P.K., Mokoena, M.P. and Gqaleni, N. (2010). Advantages of traditional lactic acid bacteria fermentation of food in Africa. *Current research, technology and education topics in applied microbiology and microbial biotechnology, 2,* pp.1160-1167.

Chiang, Y.W., Chye, F.Y. and Mohd Ismail, A. (2006). Microbial diversity and proximate composition of *Tapai*, A Sabah's fermented beverage. *Malaysian Journal of Microbiology, 2*(1), pp.1-6.

Chiang, Y.W., Chye, F.Y. and Mohd Ismail, A. (2006). Microbial diversity and proximate composition of Tapai, A Sabah's fermented beverage*. Malaysian Journal of Microbiology, 2*(1), pp.1-6.

Chick, H., Shin, H.S. and Ustunol, Z. (2001). Growth and acid production by lactic acid bacteria and *bifidobacteria* grown in skim milk containing honey. *Journal of Food Science, 66*(3), pp.478-481.

Chiu, C.H., Lu, T.Y., Tseng, Y.Y. and Pan, T.M. (2006). The effects of *Lactobacillus*-fermented milk on lipid metabolism in hamsters fed on high-cholesterol diet. *Applied Microbiology and Biotechnology, 71*(2), pp.238-245.

Chojnacka, K. (2010). Fermentation products. *Chemical engineering and chemical process technology*, pp.12.

Coconnier, M.H., Klaenhammer, T.R., Kerneis, S., Bernet, M.F. and Servin, A.L. (1992). Protein-mediated adhesion of *Lactobacillus acidophilus* BG2FO4 on human enterocyte and mucus-secreting cell lines in culture. *Appl. Environ. Microbiol., 58*(6), pp.2034-2039.

Cooke, G., Behan, J. and Costello, M. (2006). Newly identified vitamin K-producing bacteria isolated from the neonatal faecal flora*. Microbial ecology in health and disease, 18*(3-4), pp.133-138.

Corcoran, B.M., Stanton, C., Fitzgerald, G.F. and Ross, R.P. (2005). Survival of probiotic *lactobacilli* in acidic environments is enhanced in the presence of metabolizable sugars. *Appl. Environ. Microbiol., 71*(6), pp.3060-3067.

Crawford, S.E., Ramani, S., Tate, J.E., Parashar, U.D., Svensson, L., Hagbom, M., Franco, M.A., Greenberg, H.B., O'Ryan, M., Kang, G. and Desselberger, U. (2017). Rotavirus infection. *Nature Reviews Disease Primers, 3*(1), pp.1-16.

Cunningham-Rundles, S., Ahrné, S., Bengmark, S., Johann-Liang, R., Marshall, F., Metakis, L., Califano, C., Dunn, A.M., Grassey, C., Hinds, G. and Cervia, J.

(2000). Probiotics and immune response. *The American journal of gastroenterology, 95*(1), pp.S22-S25.

Curto, A.L., Pitino, I., Mandalari, G., Dainty, J.R., Faulks, R.M. and Wickham, M.S.J. (2011). Survival of probiotic *lactobacilli* in the upper gastrointestinal tract using an in vitro gastric model of digestion. *Food microbiology, 28*(7), pp.1359-1366.

Daba, H., Pandian, S., Gosselin, J.F., Simard, R.E., Huang, J. and Lacroix, C. (1991). Detection and activity of a bacteriocin produced by *Leuconostoc mesenteroides*. *Appl. Environ. Microbiol., 57*(12), pp.3450-3455.

Dalié, D.K.D., Deschamps, A.M. and Richard-Forget, F. (2010). Lactic acid bacteria–Potential for control of mould growth and mycotoxins: *A review. Food control, 21*(4), pp.370-380.

Dave, R.I. and Shah, N.P. (1997). Characteristics of bacteriocin produced by *Lactobacillus acidophilus* LA-1. *International dairy journal, 7*(11), pp.707-715.

Davis, C. (2014). Enumeration of probiotic strains: review of culture-dependent and alternative techniques to quantify viable bacteria. *Journal of microbiological methods, 103*, pp.9-17.

de Man, J.C., Rogosa, M. and Sharpe, M.E. (1960) A medium for the cultivation of lactobacilli. J. *Appl. Bacteriol. 23*, 130-135.

Degnan, F.H. (2008). The US Food and Drug Administration and probiotics: regulatory categorization. *Clinical infectious diseases, 46*(Supplement_2), pp.S133-

S136.

Desimone, C. (1984). The adjuvant effect of yoghurt on gamma interferon by Con-A stimulated human lymphocytes*. Nutr Rep Int 33*, 419-433.

Devi, S.M., Archer, A.C. and Halami, P.M. (2015). Screening, characterization and in vitro evaluation of probiotic properties among lactic acid bacteria through comparative analysis. *Probiotics and antimicrobial proteins, 7*(3), pp.181-192.

Diana, C.R., Humberto, H.S. and Jorge, Y.F. (2015). Probiotic properties of *Leuconostoc mesenteroides* isolated from aguamiel of *Agave salmiana*. *Probiotics and antimicrobial proteins, 7*(2), pp.107-117.

Dinh, Q.N., Drummond, G.R., Sobey, C.G. and Chrissobolis, S. (2014). Roles of inflammation, oxidative stress, and vascular dysfunction in hypertension. *BioMed research international,* 2014.

Djien, K.S. (1972). Tape fermentation. *Appl. Environ. Microbiol., 23*(5), pp.976-978.

Dobson, C.M., Deneer, H., Lee, S., Hemmingsen, S., Glaze, S. and Ziola, B. (2002). Phylogenetic analysis of the genus *Pediococcus*, including *Pediococcus claussenii sp. nov*., a novel lactic acid bacterium isolated from beer. *International journal of systematic and evolutionary microbiology, 52*(6), pp.2003-2010.

Donohue, D.C, Deighton, M., Ahokas, J.T., Salminen, S. (1993). Toxicity of lactic acid bacteria. *Marcel Dekker Inc, New York*, pp.307-313.

Donohue, D.C. and Salminen, S. (1996). Safety of probiotic bacteria. *Asia pacific journal of clinical nutrition, 5,* pp.25-28.

Duffy, L.C., Zielezny, M.A., Riepenhoff-Talty, M., Dryja, D., Sayahtaheri-Altaie, S., Griffiths, E., Ruffin, D., Barrett, H., Rossman, J. and Ogra, P.L. (1994). Effectiveness of *Bifidobacterium bifidum* in mediating the clinical course of murine rotavirus diarrhea. *Pediatric research, 35*(6), pp.690-695.

Elamin, E.E., Masclee, A.A., Dekker, J., Pieters, H.J. and Jonkers, D.M. (2013). Short-chain fatty acids activate AMP-activated protein kinase and ameliorate ethanol-induced intestinal barrier dysfunction in Caco-2 cell monolayers. *The Journal of nutrition, 143*(12), pp.1872-1881.

El-Jeni, R., El Bour, M., Calo-Mata, P., Böhme, K., Fernández-No, I.C., Barros-Velázquez, J. and Bouhaouala-Zahar, B. (2016). In vitro probiotic profiling of novel *Enterococcus faecium* and *Leuconostoc mesenteroides* from Tunisian freshwater fishes. *Canadian journal of microbiology, 62*(1), pp.60-71.

Elo, S., Saxelin, M. and Salminen, S. (1991). Attachment of *Lactobacillus casei* strain *GG* to human colon carcinoma cell line Caco-2: comparison with other dairy strains. *Letters in Applied Microbiology, 13*(3), pp.154-156.

Erkkilä, S. and Petäjä, E. (2000). Screening of commercial meat starter cultures at low pH and in the presence of bile salts for potential probiotic use. *Meat science, 55*(3), pp.297-300.

Feng, X.M., Eriksson, A.R. and Schnürer, J. (2005). Growth of lactic acid bacteria and *Rhizopus oligosporus* during barley tempeh fermentation. *International Journal of Food Microbiology, 104*(3), pp.249-256.

Fernandes, C.F., Shahani, K.M. and Amer, M.A. (1987). Therapeutic role of dietary *lactobacilli* and *lactobacillic* fermented dairy products. *FEMS Microbiology Reviews, 3*(3), pp.343-356.

Food and Agriculture Organization and World Health Organization. (2006). *Probiotics in food: Health and nutritional properties and guidelines for evaluation*. FAO.

Fuller, R. (1989). Probiotic in man and animals. J. *Appl. Bacteriol., 66*, pp.131-139.

Fuller, R. (1992). History and development of probiotics. *In Probiotics,* pp. 1-8. Springer, Dordrecht.

Fuller, R. (1992). Probiotics: The scientific basis, Chapman & Hall. London

Gade, J. and Thorn, F. (1989). Paraghurt for patients with irritable bowel syndrome: a controlled clinical investigation from general practice. *Scandinavian journal of primary health care, 7*(1), pp.23-26.

Gandjar, I. (2003). *Tapai* from cassava and cereals. *In Proceedings of the 1st International Symposium and Workshop on Insight into the World of Indigenous Fermented Foods for Technology Development and Food Safety, Aug* (pp. 13-17).

Gibson, G.R., Ottaway, P.B. and Rastall, R.A. (2000). Prebiotics: new developments in functional foods. Chandos.

Gill, H., Rutherfurd, K., Cross, M. and Gopal, P. (2001). Enhancement of immunity in the elderly by dietary supplementation with the probiotic *Bifidobacterium lactis* HN019. *The American Journal of Clinical Nutrition, 74*(6), pp.833-839.

Gilliland, S.E., Staley, T.E. and Bush, L.J. (1984). Importance of bile tolerance of *Lactobacillus acidophilus* used as a dietary adjunct. *Journal of dairy science, 67*(12), pp.3045-3051.

Giraffa, G. (2004). Studying the dynamics of microbial populations during food fermentation. *FEMS Microbiology Reviews, 28*(2), pp.251-260.

Gogineni, V.K., Morrow, L.E., Gregory, P.J. and Malesker, M.A. (2013). Probiotics: history and evolution. *J Anc Dis Prev Rem, 1*(2), pp.1-7.

Goldin, B.R. and Gorbach, S.L. (1984). The effect of milk and *lactobacillus* feeding on human intestinal bacterial enzyme activity. *The American journal of clinical nutrition, 39*(5), pp.756-761.

Goldin, B.R., Gorbach, S.L., Saxelin, M., Barakat, S., Gualtieri, L. and Salminen, S. (1992). Survival of *Lactobacillus species* strain *GG* in human gastrointestinal tract. *Digestive diseases and sciences, 37*(1), pp.121-128.

Goldin, B.R., Gualtieri, L.J. and Moore, R.P. (1996). The effect of *Lactobacillus GG* on the initiation and promotion of DMH-induced intestinal tumors in the rat.

Goldin, B.R., Swenson, L., Dwyer, J., Sexton, M. and Gorbach, S.L. (1980). Effect of diet and *Lactobacillus acidophilus* supplements on human fecal bacterial enzymes. *Journal of the National Cancer Institute, 64*(2), pp.255-261.

Gómez-Guzmán, M., Toral, M., Romero, M., Jiménez, R., Galindo, P., Sánchez, M., Zarzuelo, M.J., Olivares, M., Gálvez, J. and Duarte, J. (2015). Antihypertensive effects of probiotics *Lactobacillus* strains in spontaneously hypertensive rats. *Molecular nutrition & food research, 59*(11), pp.2326-2336.

Gorbach, S.L. (2000). Probiotics and gastrointestinal health. *The American journal of gastroenterology, 95*(1), pp.S2-S4.

Gourama, H. and Bullerman, L.B. (1995). Antimycotic and antiaflatoxigenic effect of lactic acid bacteria: a review. *Journal of Food Protection, 58*(11), pp.1275-1280.

Guandalini, S., Pensabene, L., Zikri, M.A., Dias, J.A., Casali, L.G., Hoekstra, H., Kolacek, S., Massar, K., Micetic–Turk, D., Papadopoulou, A. and de Sousa, J.S. (2000). *Lactobacillus GG* administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial. *Journal of pediatric gastroenterology and nutrition, 30*(1), pp.54-60.

Guerra, N.P., Bernárdez, P.F., Méndez, J., Cachaldora, P. and Castro, L.P. (2007). Production of four potentially probiotic lactic acid bacteria and their evaluation as feed additives for weaned piglets. *Animal Feed Science and Technology, 134*(1-2), pp.89-107.

Guslandi, M., Mezzi, G., Sorghi, M. and Testoni, P.A. (2000). *Saccharomyces boulardii* in maintenance treatment of Crohn's disease. *Digestive diseases and sciences, 45*(7), pp.1462-1464.

Haakensen, M., Schubert, A. and Ziola, B. (2008). Multiplex PCR for putative *Lactobacillus* and *Pediococcus* beer-spoilage genes and ability of gene presence to predict growth in beer*. Journal of the American Society of Brewing Chemists, 66*(2), pp.63-70.

Haddaji, N., Mahdhi, A.K., Krifi, B., Ismail, M.B. and Bakhrouf, A. (2015). Change in cell surface properties of *Lactobacillus casei* under heat shock treatment. *FEMS microbiology letters, 362*(9), p.fnv047.

Halpern, G.M., Prindiville, T., Blankenburg, M., Hsia, T. and Gershwin, M.E. (1996). Treatment of irritable bowel syndrome with Lacteol Fort: a randomized, double-blind, cross-over trial. *American Journal of Gastroenterology, 91*(8).

Hata, Y., Yamamoto, M., Ohni, M., Nakajima, K., Nakamura, Y. and Takano, T. (1996). A placebo-controlled study of the effect of sour milk on blood pressure in hypertensive subjects. *The American journal of clinical nutrition, 64*(5), pp.767-771.

Havenaar R. and Huis In’t Veld MJH. (1992). Probiotics: a general view. In: Lactic acid bacteria in health and disease. *Vol 1. Amsterdam: Elsevier Applied Science Publishers*.

Hesseltine, C.W., Rogers, R. and Winarno, F.G. (1988). Microbiological studies on amylolytic oriental fermentation starters. *Mycopathologia, 101*(3), pp.141-155.

Holzapfel, W.H., Haberer, P., Snel, J., Schillinger, U. and in't Veld, J.H.H. (1998). Overview of gut flora and probiotics. *International journal of food microbiology, 41*(2), pp.85-101.

Huang, Y. and Adams, M.C. (2004). In vitro assessment of the upper gastrointestinal tolerance of potential probiotic dairy propionibacteria. *International Journal of Food Microbiology, 91*(3), pp.253-260.

Huang, Y.C., Wu, B.H., Chu, Y.L., Chang, W.C. and Wu, M.C. (2018). Effects of tempeh fermentation with *lactobacillus plantarum* and *rhizopus oligosporus* on streptozotocin-induced type ii diabetes mellitus in rats. *Nutrients, 10*(9), p.1143.

Hughes, D.B. and Hoover, D.G. (1991). Bifidobacteria: their potential for use in American dairy products. *Food technology (Chicago), 45(*4), pp.74-83.

Immerstrand, T., Paul, C.J., Rosenquist, A., Deraz, S., Mårtensson, O.B., Ljungh, Å., Blücher, A., Öste, R., Holst, O. and Karlsson, E.N. (2010). Characterization of the properties of *Pediococcus parvulus* for probiotic or protective culture use. *Journal of food protection, 73*(5), pp.960-966.

Ishihara, K., Miyakawa, H., Hasegawa, A., Takazoe, I. and Kawai, Y. (1985). Growth inhibition of *Streptococcus* mutans by cellular extracts of human intestinal lactic acid bacteria. *Infection and immunity, 49*(3), pp.692-694.

Isolauri, E. (2004). Dietary modification of atopic disease: Use of probiotics in the prevention of atopic dermatitis. *Current allergy and asthma reports, 4*(4), pp.270-275.

Jayashree, S., Jayaraman, K. and Kalaichelvan, G. (2010). Isolation, screening and characterization of riboflavin producing lactic acid bacteria from *Katpadi*, Vellore district. *Recent Research in Science and Technology, 2*(1).

Jin, L.Z., Ho, Y.W., Abdullah, N. and Jalaludin, S. (1998). Acid and bile tolerance of *Lactobacillus* isolated from chicken intestine. *Letters in applied microbiology, 27*(3), pp.183-185.

Kanauchi, O., Fujiyama, Y., Mitsuyama, K., Araki, Y., Ishii, T., Nakamura, T., Hitomi, Y., Agata, K., Saiki, T., Andoh, A. and Toyonaga, A. (1999). Increased growth of *Bifidobacterium* and *Eubacterium* by germinated barley foodstuff, accompanied by enhanced butyrate production in healthy volunteers. *International journal of molecular medicine, 3*(2), pp.175-184.

Kato, K., Mizuno, S., Umesaki, Y., Ishii, Y., Sugitani, M., Imaoka, A., Otsuka, M., Hasunuma, O., Kurihara, R., Iwasaki, A. and Arakawa, Y. (2004). Randomized placebo-controlled trial assessing the effect of *bifidobacteria*-fermented milk on active ulcerative colitis. *Alimentary pharmacology & therapeutics, 20*(10), pp.1133-1141.

Khalil, E.S., Manap, A., Yazid, M., Mustafa, S., Alhelli, A.M. and Shokryazdan, P. (2018). Probiotic properties of exopolysaccharide-producing *Lactobacillus* strains isolated from *Tempoyak*. *Molecules, 23*(2), p.398.

Kilic, G.B., Kilic, B., Kuleasan, H. and Karahan, A.G. (2010). Effect of probiotics and α-tocopherol applications on microbial flora of rat gastrointestinal tract. *Journal of Animal and Veterinary Advances, 9*(14), pp.1972-1977.

Kim, J.A., Bayo, J., Cha, J., Choi, Y.J., Jung, M.Y., Kim, D.H. and Kim, Y. (2019). Investigating the probiotic characteristics of four microbial strains with potential application in feed industry. *PloS one, 14*(6), p.e0218922.

Kim, M., Nam, D.G., Kim, S.B., Im, P., Choe, J.S. and Choi, A.J. (2018). Enhancement of viability, acid, and bile tolerance and accelerated stability in lyophilized *Weissella cibaria* JW 15 with protective agents*. Food Science & Nutrition, 6*(7), pp.1904-1913.

Kiple, K.F. and Ornelas, K. (2000). The Cambridge world history of food. Cambridge University Press.

Kongo, J.M. (2013). *Lactic Acid Bacteria: R*. BoD–Books on Demand.

Kormin, S., Rusul, G., Radu, S. and Ling, F.H. (2001). Bacteriocin-producing lactic acid bacteria isolated from traditional fermented food. *The Malaysian journal of medical sciences: MJMS, 8*(1), p.63.

Kosikowski, F.V. and Mistry, V.V. (1997). Cheese and fermented milk foods. Volume 2: procedures and analysis. Cheese and fermented milk foods. *Volume 2: procedures and analysis*., (Ed. 3).

Kumar, R., Bansal, P., Singh, J., Dhanda, S. and Bhardwaj, J.K. (2020). Aggregation, adhesion and efficacy studies of probiotic candidate *Pediococcus acidilactici* NCDC 252: a strain of dairy origin. *World Journal of Microbiology and Biotechnology, 36*(1), p.10.

Kyne, L. and Kelly, C.P. (2001). Recurrent *Clostridium difficilediarrhoea*. *Gut, 49*(1), pp.152-153.

Le, B. and Yang, S.H. (2019). Effect of potential probiotic *Leuconostoc mesenteroides* FB111 in prevention of cholesterol absorption by modulating NPC1L1/PPARα/SREBP-2 pathways in epithelial Caco-2 cells. *International Microbiology, 22*(2), pp.279-287.

LeBlanc, J.G., de Giori, G.S., Smid, E.J., Hugenholtz, J. and Sesma, F. (2007). Folate production by lactic acid bacteria and other food-grade microorganisms. *Communicating current research and educational topics and trends in applied microbiology, 1*, pp.329-339.

Levy, J. (2000). The effects of antibiotic use on gastrointestinal function. *The American journal of gastroenterology, 95*(1), pp.S8-S10.

Lewenstein, A., Frigerio, G. and Moroni, M. (1979). Effect of *Streptococcus faecium* C-68, a new approach for the treatments of diarrheal diseases. *Curr. Ther. Res. 26*, pp.967-981.

Li, P., Lin, W., Liu, X., Wang, X. and Luo, L. (2016). Environmental factors affecting microbiota dynamics during traditional solid-state fermentation of Chinese *Daqu* starter. *Frontiers in microbiology, 7*, p.1237.

Lidbeck, A., Övervik, E., Rafter, J., Nord, C.E. and Gustafsson, J.Å. (1992). Effect of *Lactobacillus acidophilus* supplements on mutagen excretion in faeces and urine in humans. *Microbial Ecology in Health and Disease, 5*(1), pp.59-67.

Liem, I.T., Steinkraus, K.H. and Cronk, T.C. (1977). Production of vitamin B-12 in *tempeh*, a fermented soybean food. *Appl. Environ. Microbiol., 34*(6), pp.773-776.

Liong, M.T. and Shah, N.P. (2005). Acid and bile tolerance and cholesterol removal ability of *lactobacilli* strains. *Journal of dairy science, 88*(1), pp.55-66.

Liong, M.T. and Shah, N.P. (2005)a. Acid and bile tolerance and cholesterol removal ability of *lactobacilli* strains. *Journal of dairy science, 88*(1), pp.55-66

Liong, M.T. and Shah, N.P. (2005)b. Acid and bile tolerance and the cholesterol removal ability of *bifidobacteria* strains*. Bioscience and microflora, 24*(1), pp.1-10.

Liu, Q., Duan, Z.P., Ha, D.K., Bengmark, S., Kurtovic, J. and Riordan, S.M. (2004). Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. *Hepatology, 39*(5), pp.1441-1449.

Loh, T.C., Harun, H.A., Foo, H.L. and Law, F.L. (2008). Effects of Feeding Spraydried Metabolite Of *Lactococcus Lactis Subsp. Lactis*-RW18 In Postweaning Rats. *International Journal of Probiotics and Prebiotics, 3*(1), p.1.

Lourens-Hattingh, A. and Viljoen, B.C. (2001). Yogurt as probiotic carrier food. *International dairy journal, 11*(1-2), pp.1-17.

Lye, H.S., Kuan, C.Y., Ewe, J.A., Fung, W.Y. and Liong, M.T. (2009). The improvement of hypertension by probiotics: effects on cholesterol, diabetes, renin, and phytoestrogens. *International journal of molecular sciences, 10*(9), pp.3755-3775.

Malhotra, S.L. (1977). Dietary factors in a study of cancer colon from cancer registry, with special reference to the role of saliva, milk and fermented milk products and vegetable fibre. *Medical hypotheses, 3*(3), pp.122-126.

Mandal, S., Puniya, A.K. and Singh, K. (2006). Effect of alginate concentrations on survival of microencapsulated *Lactobacillus casei* NCDC-298. *International Dairy Journal, 16*(10), pp.1190-1195.

Mandal, V., Sen, S.K. and Mandal, N.C. (2009). Effect of prebiotics on bacteriocin production and cholesterol lowering activity of *Pediococcus acidilactici* LAB 5. *World Journal of Microbiology and Biotechnology, 25*(10), pp.1837-1847.

Marianelli, C., Cifani, N. and Pasquali, P. (2010). Evaluation of antimicrobial activity of probiotic bacteria against *Salmonella enterica subsp. enterica serovar typhimurium* 1344 in a common medium under different environmental conditions. *Research in microbiology, 161*(8), pp.673-680.

Marketresearchfuture.com (2020). *Probiotic Drinks Market Trends, Size, Share And*

Global Analysis, 2024 | MRFR. [online] Available at: <https://www.marketresearchfuture.com/reports/probiotic-drinks-market-5001> [Accessed 20 March 2020].

Marshall, R.T. (1992). Standard methods for the examination of dairy products.

Marteau, P.R., Vrese, M.D., Cellier, C.J. and Schrezenmeir, J. (2001). Protection from gastrointestinal diseases with the use of probiotics. *The American journal of clinical nutrition, 73*(2), pp.430s-436s.

Matsuzaki, T. and Chin, J. (2000). Modulating immune responses with probiotic bacteria. *Immunology and cell biology, 78*(1), pp.67-73.

Matsuzaki, T., Takagi, A., Ikemura, H., Matsuguchi, T. and Yokokura, T. (2007). Intestinal microflora: probiotics and autoimmunity. *The Journal of nutrition, 137*(3), pp.798S-802S.

Mättö, J., Malinen, E., Suihko, M.L., Alander, M., Palva, A. and Saarela, M. (2004). Genetic heterogeneity and functional properties of intestinal *bifidobacteria*. *Journal of Applied Microbiology, 97*(3), pp.459-470.

McGovern, P.E. (2009). Uncorking the past: the quest for wine, beer, and other alcoholic beverages. Univ of California Press.

Metchnikoff, E. and Metchnikoff, I.I. (1908). The Prolongation of Life: Optimistic Studies. Our post human future. *Consequences of the Biotechnology Revolution. New York, London: GP Putnam's Sons. Available from: http://www. books. google.*

com/books.

Miles, A.A., Misra, S.S. and Irwin, J.O. (1938). The estimation of the bactericidal power of the blood. *Epidemiology & Infection, 38*(6), pp.732-749.

Mittal, V.V., Sharma, B.C., Sharma, P. and Sarin, S.K. (2011). A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy. *European journal of gastroenterology & hepatology, 23*(8), pp.725-732.

Mokoena, M.P., Chelule, P.K. and Gqaleni, N. (2005). Reduction of fumonisin B1 and zearalenone by lactic acid bacteria in fermented maize meal. *Journal of food protection, 68*(10), pp.2095-2099.

Mokoena, M.P., Chelule, P.K. and Gqaleni, N. (2006). The toxicity and decreased concentration of aflatoxin B1 in natural lactic acid fermented maize meal. *Journal of applied microbiology, 100*(4), pp.773-777.

Momose, H. (1979). Toxicological studies on *Bifidobacterium longum* BB-536. Ouyou Yakuri, 17, pp.881-887.

Monteagudo-Mera, A., Rastall, R.A., Gibson, G.R., Charalampopoulos, D. and Chatzifragkou, A. (2019). Adhesion mechanisms mediated by probiotics and prebiotics and their potential impact on human health. *Applied microbiology and biotechnology, 103*(16), pp.6463-6472.

Mora, D., Fortina, M.G., Parini, C. and Manachini, P.L. (1997). Identification of

Pediococcus acidilactici and *Pediococcus pentosaceus* based on 16S rRNA and ldhD gene-targeted multiplex PCR analysis. *FEMS microbiology letters, 151*(2), pp.231-236.

Mosha, T.C. and Vicent, M.M. (2004). Nutritional value and acceptability of homemade maize/sorghum-based weaning mixtures supplemented with rojo bean flour, ground sardines and peanut paste. *International journal of food sciences and nutrition, 55*(4), pp.301-315.

Motherway, M.O.C., Zomer, A., Leahy, S.C., Reunanen, J., Bottacini, F., Claesson, M.J., O'Brien, F., Flynn, K., Casey, P.G., Munoz, J.A.M. and Kearney, B. (2011). Functional genome analysis of *Bifidobacterium breve* UCC2003 reveals type IVb tight adherence (Tad) pili as an essential and conserved host-colonization factor. *Proceedings of the National Academy of Sciences, 108*(27), pp.11217-11222.

Motta, L., Blancato, G., Scornavacca, G., De, M.L., Vasquez, E., Gismondo, M.R., Lo, A.B. and Chisari, G. (1991). Study on the activity of a therapeutic bacterial combination in intestinal motility disorders in the aged. *La Clinica terapeutica, 138*(1), pp.27-35.

Mouli, V.P., Benjamin. J., Singh, M.B., Mani, K., Garg, S.K., Saraya, A. (2014). Effects of probiotic VSL#3 in the treatment of minimal hepatic encephalopathy: A non-inferiority randomized controlled trial. Hepatol Res.

Muñoz-Provencio, D., Rodríguez-Díaz, J., Collado, M.C., Langella, P., Bermúdez-Humarán, L.G. and Monedero, V. (2012). Functional analysis of the *Lactobacillus*

casei BL23 sortases. *Applied and environmental microbiology, 78*(24), pp.8684-8693.

Nakamura, Y., Yamamoto, N., Sakai, K. and Takano, T. (1995). Antihypertensive effect of sour milk and peptides isolated from it that are inhibitors to angiotensin I-converting enzyme. *Journal of dairy science, 78*(6), pp.1253-1257.

Nor, N.M., Mousavi, S.S., Mohamad, R., Ling, F.H. and Rahim, R.A. (2008). Screening of Lactic Acid Bacteria for Folic Acid Production from Various Sources. In 30th Symposium of Malaysian Society for Microbiology.

Nout, M.J.R. and Sarkar, P.K. (1999). Lactic acid food fermentation in tropical climates. In Lactic acid bacteria: Genetics, metabolism and applications, pp. 395-401. Springer, Dordrecht.

Nout, M.R. (2009). Rich nutrition from the poorest–Cereal fermentations in Africa and Asia. *Food Microbiology, 26*(7), pp.685-692.

Novik, G.I., Astapovich, N.I. and Ryabaya, N.E. (2007). Production of hydrolases by lactic acid bacteria and *bifidobacteria* and their antibiotic resistance. *Applied Biochemistry and Microbiology, 4*3(2), pp.164-172.

O'Connor, E.B., Barrett, E., Fitzgerald, G., Hill, C., Stanton, C. and Ross, R.P. (2005). Production of vitamins, exopolysaccharides and bacteriocins by probiotic bacteria. Probiotic dairy products, pp.167-194.

Oberman, H. (1985). Fermented milk. *Microbiology of fermented foods, 1*, pp.167-196.

Obiri-Danso, K., Ellis, W.O., Simpson, B.K. and Smith, J.P. (1997). Suitability of high lysine maize, Obatanpa for 'kenkey'production. *Food Control, 8*(3), pp.125-129.

Ooi, S.T. (2010). Effects of Feeding Probiotic Metabolites on the Growth and Carcass Characteristics of Broilers Chicken (Doctoral dissertation, Universiti Putra Malaysia).

O'sullivan, M.G., Thornton, G., O'sullivan, G.C. and Collins, J.K. (1992). Probiotic bacteria: myth or reality?. *Trends in food science & technology, 3*, pp.309-314.

Ouwehand, A.C., Lagström, H., Suomalainen, T. and Salminen, S. (2002). Effect of probiotics on constipation, fecal azoreductase activity and fecal mucin content in the elderly. *Annals of nutrition and metabolism*, *46*(3-4), pp.159-162.

Ouwehand, A.C., Salminen, S. and Isolauri, E. (2002). Probiotics: an overview of beneficial effects. *In Lactic acid bacteria: genetics, metabolism and applications*, pp. 279-289. Springer, Dordrecht.

Pan, W.H., Li, P.L. and Liu, Z. (2006). The correlation between surface hydrophobicity and adherence of *Bifidobacterium* strains from centenarians' faeces. *Anaerobe, 12*(3), pp.148-152.

Pan, X., Chen, F., Wu, T., Tang, H. and Zhao, Z. (2009). The acid, bile tolerance and antimicrobial property of *Lactobacillus acidophilus* NIT. *Food Control, 20*(6), pp.598-602.

Parker, R.B. (1974). Probiotics, the other half of the antibiotic story. *Anim Nutr Health, 29*, pp.4-8.

Parvez, S., Malik, K.A., Ah Kang, S. and Kim, H.Y. (2006). Probiotics and their fermented food products are beneficial for health. *Journal of applied microbiology, 100*(6), pp.1171-1185.

Patel, A., Lindström, C., Patel, A., Prajapati, J.B. and Holst, O. (2012). Probiotic properties of exopolysaccharide producing lactic acid bacteria isolated from vegetables and traditional Indian fermented foods. *International Journal of Fermented Foods, 1*(1), pp.87-101.

Pearce, J.L. and Hamilton, J.R. (1974). Controlled trial of orally administered *lactobacilli* in acute infantile diarrhea. *The Journal of pediatrics, 84*(2), pp.261-262.

Peng, L., Li, Z.R., Green, R.S., Holzman, I.R. and Lin, J. (2009). Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. *The Journal of nutrition, 139*(9), pp.1619-1625.

Piepenbrink, K.H. and Sundberg, E.J. (2016). Motility and adhesion through type IV pili in Gram-positive bacteria. *Biochemical Society transactions, 44*(6), pp.1659-1666.

Pisol, B., Abdullah, N., Khalil, K.A. and Nuraida, L. (2015). Isolation and identification of lactic acid bacteria from different stages of traditional Malaysian *tempeh* production. *Malaysian Journal of Microbiology, 11*(4), pp.358-364.

Pittet, V., Abegunde, T., Marfleet, T., Haakensen, M., Morrow, K., Jayaprakash, T., Schroeder, K., Trost, B., Byrns, S., Bergsveinson, J. and Kusalik, A. (2012). Complete genome sequence of the beer spoilage organism *Pediococcus claussenii* ATCC BAA-

344T.

Porto, M.C.W., Kuniyoshi, T.M., Azevedo, P.O.S., Vitolo, M. and Oliveira, R.P.D.S. (2017). *Pediococcus spp*.: an important genus of lactic acid bacteria and pediocin producers. *Biotechnology Advances, 35*(3), pp.361-374.

Promega.com. *2020. Promega Corporation.* [online] Available at: <http://www.promega.com/> [Accessed 17 June 2020].

Prommadee, P., Wunwiboon, G., Kees, L. and Sunee, N. (2012). Characterization of *Lactobacillus johnsonii* KUNN19-2 and *Pediococcus pentosaceus* KUNNE6-1 isolated from thai-style fermented pork (*Nham*) for their probiotic properties in the gastrointestinal tract and immunomodulation. *Kasetsart Journal: Natural Science, 46*(3), pp.440-450.

Radziwill-Bienkowska, J.M., Robert, V., Drabot, K., Chain, F., Cherbuy, C., Langella, P., Thomas, M., Bardowski, J.K., Mercier-Bonin, M. and Kowalczyk, M. (2017). Contribution of plasmid-encoded peptidase S8 (PrtP) to adhesion and transit in the gut of *Lactococcus lactis* IBB477 strain. *Applied microbiology and biotechnology, 101*(14), pp.5709-5721.

Rajalakshmi, R. and Vanaja, K. (1967). Chemical and biological evaluation of the effects of fermentation on the nutritive value of foods prepared from rice and grams. *British journal of nutrition, 21*(2), pp.467-473.

Ramasamy, K., Rahman, N.Z.A., Chin, S.C., Alitheen, N.J., Abdullah, N. and Wan,

H.Y. (2012). Probiotic potential of lactic acid bacteria from fermented Malaysian food or milk products. *International journal of food science & technology, 47*(10), pp.2175-2183.

Rath, H.C. (2003). The role of endogenous bacterial flora: bystander or the necessary prerequisite?. *European journal of gastroenterology & hepatology, 15*(6), pp.615-620.

Ren, D., Zhu, J., Gong, S., Liu, H. and Yu, H. (2018). Antimicrobial characteristics of lactic acid bacteria isolated from homemade fermented foods. *BioMed research international, 2018.*

Resta-Lenert, S. and Barrett, K.E. (2003). Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive *Escherichia coli* (EIEC). *Gut, 52*(7), pp.988-997.

Rettger, L.F. and Cheplin, H.A. (1921). *A Treatise on the Transformation of the Intestinal Flora: With Special Reference to the Implantation of Bacillus Acidophilus* (Vol. 13). Yale University Press.

Rettger, L.F., Levy, M.N., Weinstein, L. and Weiss, J.E. (1935). *Lactobacillus acidophilus* and its Therapeutic Application. *Lactobacillus acidophilus and its Therapeutic Application.*

Reunanen, J., von Ossowski, I., Hendrickx, A.P., Palva, A. and de Vos, W.M. (2012). Characterization of the SpaCBA pilus fibers in the *probiotic Lactobacillus rhamnosus GG*. *Applied and environmental microbiology, 78*(7), pp.2337-2344.

Rinkinen, M., Mättö, J., Salminen, S., Westermarck, E. and Ouwehand, A.C. (2000). *In vitro* adhesion of lactic acid bacteria to canine small intestinal mucus. *Journal of Animal Physiology and Animal Nutrition, 84*(1‐2), pp.43-47.

Riss, T.L., Moravec, R.A., Niles, A.L., Duellman, S., Benink, H.A., Worzella, T.J. and Minor, L. (2016). Cell viability assays. *In Assay Guidance Manual [Internet].* Eli Lilly & Company and the National Center for Advancing Translational Sciences.

Ross, R.P., Desmond, C., Fitzgerald, G.F. and Stanton, C. (2005). Overcoming the technological hurdles in the development of probiotic foods. *Journal of Applied Microbiology, 98*(6), pp.1410-1417.

Roy, M.J., Dionne, S., Marx, G., Qureshi, I., Sarma, D., Levy, E. and Seidman, E.G. (2009). *In vitro* studies on the inhibition of colon cancer by butyrate and carnitine. *Nutrition, 25*(11-12), pp.1193-1201.

Ruiz, L., Margolles, A. and Sánchez, B. (2013). Bile resistance mechanisms in *Lactobacillus* and *Bifidobacterium. Fr*

Ruseler-van Embden, J.G.H., Van Lieshout, L.M.C., Gosselink, M.J. and Marteau, P. (1995). Inability of *Lactobacillus casei* strain *GG, L. acidophilus,* and *Bifidobacterium bifidum* to degrade intestinal mucus glycoproteins. *Scandinavian journal of gastroenterology, 30*(7), pp.675-680.

Saarela, M., Lähteenmäki, L., Crittenden, R., Salminen, S. and Mattila-Sandholm, T. (2002). Gut bacteria and health foods—the European perspective. *International*

journal of food microbiology, 78(1-2), pp.99-117.

Saarela, M., Mogensen, G., Fonden, R., Mättö, J. and Mattila-Sandholm, T. (2000). Probiotic bacteria: safety, functional and technological properties. *Journal of biotechnology, 84*(3), pp.197-215.

Saavedra, J. (2000). Probiotics and infectious diarrhea. *The American journal of gastroenterology, 95*(1), pp.S16-S18.

Saavedra, J.M., Bauman, N.A., Perman, J.A., Yolken, R.H. and Oung, I. (1994). Feeding of *Bifidobacterium bifidum* and *Streptococcus thermophilus* to infants in hospital for prevention of diarrhoea and shedding of rotavirus. *The lancet, 344*(8929), pp.1046-1049.

Sabir, F., Beyatli, Y., Cokmus, C. and Onal-Darilmaz, D. (2010). Assessment of potential probiotic properties of *Lactobacillus spp., Lactococcus spp.,* and *Pediococcus spp.* strains isolated from kefir. *Journal of Food Science, 75*(9), pp.M568-M573.

Sanders, M.E. (2000). Considerations for use of probiotic bacteria to modulate human health*. The Journal of nutrition, 130*(2), pp.384S-390S.

Santosa, S., Farnworth, E. and Jones, P.J. (2006). Probiotics and their potential health claims. *Nutrition reviews, 64*(6), pp.265-274.

Sartor, R.B. (1995). Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn’s disease. *Gastroenterol Clin North Am, 24*, pp. 475-507

Sawada, H., Furushiro, M., Hirai, K., Motoike, M., Watanabe, T. and Yokokura, T. (1990). Purification and characterization of an antihypertensive compound from *Lactohacillus casei*. *Agricultural and biological chemistry, 54*(12), pp.3211-3219.

Schnürer, J. and Magnusson, J. (2005). Antifungal lactic acid bacteria as biopreservatives. *Trends in Food Science & Technology, 16*(1-3), pp.70-78.

Schumann, W. (2003). The *Bacillus subtilis* heat shock stimulon. *Cell stress & chaperones, 8*(3), p.207.

Segal, I., Hassan, H., Walker, A.R.P., Becker, P. and Braganza, J. (1995). Fecal short chain fatty acids in South African urban Africans and whites. *Diseases of the colon & rectum, 38*(7), pp.732-734.

Sen, S., Mullan, M.M., Parker, T.J., Woolner, J.T., Tarry, S.A. and Hunter, J.O. (2002). Effect of *Lactobacillus plantarum* 299v on colonic fermentation and symptoms of irritable bowel syndrome*. Digestive diseases and sciences, 47*(11), pp.2615-2620.

Seo, B.J., Rather, I.A., Kumar, V.J.R., Choi, U.H., Moon, M.R., Lim, J.H. and Park, Y.H. (2012). Evaluation of *Leuconostoc mesenteroides* YML003 as a probiotic against low-pathogenic avian influenza (H9N2) virus in chickens. *Journal of applied microbiology, 113*(1), pp.163-171.

Servin, A.L. (2004). Antagonistic activities of *lactobacilli* and *bifidobacteria* against microbial pathogens. *FEMS microbiology reviews, 28*(4), pp.405-440.

Shahani, K.M. and Friend, B.A. (1983). Properties of and prospects for cultured dairy

foods. In Symposium series-Society for Applied Bacteriology.

Shanahan, F. (2001). Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. *Gastroenterology, 120*(3), pp.622-635.

Sharafedtinov, K.K., Plotnikova, O.A., Alexeeva, R.I., Sentsova, T.B., Songisepp, E., Stsepetova, J., Smidt, I. and Mikelsaar, M. (2013). Hypocaloric diet supplemented with probiotic cheese improves body mass index and blood pressure indices of obese hypertensive patients-a randomized double-blind placebo-controlled pilot study. *Nutrition journal, 12*(1), p.138.

Sharma, B.C. and Singh, J. (2016). Probiotics in management of hepatic encephalopathy. *Metabolic brain disease, 31*(6), pp.1295-1301.

Sharma, P., Sharma, B.C., Puri, V. and Sarin, S.K. (2008). An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy. *European journal of gastroenterology & hepatology, 20*(6), pp.506-511.

Shehata, M.G., El Sohaimy, S.A., El-Sahn, M.A. and Youssef, M.M. (2016). Screening of isolated potential probiotic lactic acid bacteria for cholesterol lowering property and bile salt hydrolase activity. *Annals of Agricultural Sciences, 61*(1), pp.65-75.

Sheih, Y.H., Chiang, B.L., Wang, L.H., Liao, C.K. and Gill, H.S. (2001). Systemic immunity-enhancing effects in healthy subjects following dietary consumption of the lactic acid bacterium *Lactobacillus rhamnosus* HN001. *Journal of the American*

College of Nutrition, 20(2), pp.149-156.

Shukla, R., Iliev, I. and Goyal, A. (2014). *Leuconostoc mesenteroides* NRRL B-1149 as probiotic and its dextran with anticancer properties. *Journal of BioScience & Biotechnology, 3*(1).

Sinha, D.K. (1979). Development of a Nonfermented *Acidophilus* Milk and Testing its Properties. MS thesis, University of Nebraska-Lincoln, U.S.A.

Solga, S.F. (2003). Probiotics can treat hepatic encephalopathy*. Medical hypotheses, 61*(2), pp.307-313.

Spanhaak, S., Havenaar, R. and Schaafsma, G. (1998). The effect of consumption of milk fermented by *Lactobacillus casei* strain Shirota on the intestinal microflora and immune parameters in humans. *European Journal of Clinical Nutrition, 52*(12), pp.899-907.

Steinkraus, K. ed. (2004). *Industrialization of indigenous fermented foods, revised and expanded*. CRC Press.

Sukumar, G. and Ghosh, A.R. (2010). *Pediococcus spp*.–A potential probiotic isolated from *Khadi* (an Indian fermented food) and identified by 16S rDNA sequence analysis. *African Journal of Food Science, 4*(9), pp.597-602.

Surono, I.S. (2003). *In vitro* probiotic properties of indigenous dadih lactic acid bacteria. *Asian-Australasian Journal of Animal Sciences, 16*(5), pp.726-731.

SYBR™ Safe DNA Gel Stain. (2020). *www.thermofisher.com*. [online] Available at: https://www.thermofisher.com/order/catalog/product/S33102#/S33102 [Accessed 25 Feb. 2020].

Szarka, L.A. and Camilleri, M. (2012), March. Methods for the assessment of small-bowel and colonic transit. *In Seminars in nuclear medicine* (Vol. 42, No. 2, pp. 113-123). WB Saunders.

Taranto, M.P., Vera, J.L., Hugenholtz, J., De Valdez, G.F. and Sesma, F. (2003). *Lactobacillus reuteri* CRL1098 produces cobalamin. *Journal of bacteriology, 185*(18), pp.5643-5647.

Termont, S., Vandenbroucke, K., Iserentant, D., Neirynck, S., Steidler, L., Remaut, E. and Rottiers, P. (2006). Intracellular accumulation of trehalose protects *Lactococcus lactis* from freeze-drying damage and bile toxicity and increases gastric acid resistance. *Applied and environmental microbiology, 72*(12), pp.7694-7700.

Timmerman, H.M., Niers, L.E., Ridwan, B.U., Koning, C.J., Mulder, L., Akkermans, L.M., Rombouts, F.M. and Rijkers, G.T. (2007). Design of a multispecies probiotic mixture to prevent infectious complications in critically ill patients*. Clinical Nutrition, 26*(4), pp.450-459.

Toh, H., Oshima, K., Nakano, A., Takahata, M., Murakami, M., Takaki, T., Nishiyama, H., Igimi, S., Hattori, M. and Morita, H. (2013). Genomic adaptation of the *Lactobacillus casei* group. *PloS one, 8*(10), p.e75073.

Tokatli, M., Gülgör, G., Bağder Elmacı, S., Arslankoz İşleyen, N. and Özçelik, F. (2015). *In vitro* properties of potential probiotic indigenous lactic acid bacteria originating from traditional pickles. *BioMed research international,* 2015.

Tomaro-Duchesneau, C., Jones, M.L., Shah, D., Jain, P., Saha, S. and Prakash, S. (2014). Cholesterol assimilation by *Lactobacillus* probiotic bacteria: an *in vitro* investigation. *BioMed research international*, 2014

Tomic-Karovic, K. and Fanjek, J. (1962). *Acidophilus*-milk in the therapy of infantile diarrhea caused by pathogenic *E. coli*. In Annales paediatrici. *International review of pediatrics*, Vol. 199, pp. 625-634.

Underdahl, N.R., Torres-Medina, A. and Dosten, A.R. (1982). Effect of *Streptococcus faecium* C-68 in control of *Escherichia coli*-induced diarrhea in gnotobiotic pigs. *American journal of veterinary research, 43*(12), pp.2227-2232.

Uniprot.org. (2020). *Leuconostoc mesenteroides subsp. Mesenteroides (strain ATCC 8293 / NCDO 523)*. [online] Available at: https://www.uniprot.org/proteomes/UP000000362 [Accessed 25 Feb. 2020].

Van Hoorde, K., Verstraete, T., Vandamme, P. and Huys, G. (2008). Diversity of lactic acid bacteria in two Flemish artisan raw milk Gouda-type cheeses. *Food microbiology, 25*(7), pp.929-935.

Vanderhoof, J.A. (2000). Probiotics and intestinal inflammatory disorders in infants and children. *Journal of pediatric gastroenterology and nutrition, 30*, pp.S34-S38.

Verdenelli, M.C., Ghelfi, F., Silvi, S., Orpianesi, C., Cecchini, C. and Cresci, A. (2009). Probiotic properties of *Lactobacillus rhamnosus* and *Lactobacillus paracasei* isolated from human faeces. *European journal of nutrition, 48*(6), pp.355-363.

Vinderola, C.G., Prosello, W., Ghiberto, D. and Reinheimer, J.A. (2000). Viability of probiotic (*Bifidobacterium*, *Lactobacillus acidophilus* and *Lactobacillus casei*) and nonprobiotic microflora in Argentinian Fresco cheese. *Journal of Dairy Science, 83*(9), pp.1905-1911.

Vinderola, G., Binetti, A., Burns, P. and Reinheimer, J. (2011). Cell viability and functionality of probiotic bacteria in dairy products. *Frontiers in Microbiology, 2,* p.70.

Watkins, B.A. and Miller, B.F. (1983). Competitive gut exclusion of avian pathogens by *Lactobacillus acidophilus* in gnotobiotic chicks. *Poultry Science, 62*(9), pp.1772-1779.

Watkins, B.A., Miller, B.F. and Neil, D.H. (1982). *In vivo* inhibitory effects of *Lactobacillus acidophilus* against pathogenic *Escherichia coli* in gnotobiotic chicks. *Poultry Science, 61*(7), pp.1298-1308.

Wedajo, B. (2015). Lactic acid bacteria: benefits, selection criteria and probiotic potential in fermented food. *J Prob Health, 3*(2).

Whittenbury, R. (1964). Hydrogen peroxide formation and catalase activity in the lactic acid bacteria. *Microbiology, 35*(1), pp.13-26.

World Health Organization, Food and Agriculture Organization of the United Nations.

(2001) Report of a Joint FAO/WHO expert consultation of evaluations of health and nutritional properties of probiotics in food including powder milk and live lactic acid bacteria in Cordoba, Argentina. *Probiotics in Food: Health and Nutritional Properties and Guidelines for Evaluation.*

www.fishersci.com. (2020). *Invitrogen™ E-Gel™ Agarose Gels with SYBR Safe™ DNA Gel Stain, 1.2%*. [online] Available at: https://www.fishersci.com/shop/products/invitrogen-e-gel-agarose-gels-sybr-safe-dna-gel-stain-1-2/g521801#?keyword=SYBR%26reg%3B+safe+DNA+gel+stai [Accessed 25 Feb. 2020].

Yakult.co.jp. (2020). *Yakult Annual Report 2018.* [online] Available at: <https://www.yakult.co.jp/english/ir/management/pdf/ar2018.pdf> [Accessed 20 March 2020].

Yap, G. and Wan Nawawi, W. (2016). *Traditional Health Supplements In Malaysia.* [online] Krinstitute.org. Available at: <http://www.krinstitute.org/Working_Paper-@-Traditional_Health_Supplements_in_Malaysia.aspx> [Accessed 20 March 2020].

Yi, Y.J., Lim, J.M., Gu, S., Lee, W.K., Oh, E., Lee, S.M. and Oh, B.T. (2017). Potential use of lactic acid bacteria *Leuconostoc mesenteroides* as a probiotic for the removal of Pb (II) toxicity. *Journal of Microbiology, 55*(4), pp.296-303.

Zdolec, N., Dobranić, V., Zdolec, G. and Đuričić, D. (2013). Antimicrobial resistance of coagulase-negative staphylococci and lactic acid bacteria from industrially produced dairy products. *Mljekarstvo, 63*(1), pp.30-35.

Zhang, B., Zuo, F., Yu, R., Zeng, Z., Ma, H. and Chen, S. (2015). Comparative genome-based identification of a cell wall-anchored protein from *Lactobacillus plantarum* increases adhesion of *Lactococcus lactis* to human epithelial cells. *Scientific reports, 5,* p.14109.

Zhang, W., Liu, M. and Dai, X. (2013). Biological characteristics and probiotic effect of *Leuconostoc lactis* strain isolated from the intestine of black porgy fish. *Brazilian journal of microbiology, 44*(3), pp.685-691.

Zhang, Z., Zhai, H., Geng, J., Yu, R., Ren, H., Fan, H. and Shi, P. (2013). Large-scale survey of gut microbiota associated with MHE Via 16S rRNA-based pyrosequencing. *American Journal of Gastroenterology, 108*(10), pp.1601-1611.

Ziada, D.H., Soliman, H.H., El Yamany, S.A., Hamisa, M.F. and Hasan, A.M. (2013). Can *Lactobacillus acidophilus* improve minimal hepatic encephalopathy? A neurometabolite study using magnetic resonance spectroscopy. *Arab Journal of Gastroenterology, 14*(3), pp.116-122.

Zinedine, A.B.D.E.L.L.A.H., Faid, M.O.H.A.M.E.D. and Benlemlih, M.O.H.A.M.E.D. (2005). *In vitro* reduction of aflatoxin B1 by strains of lactic acid bacteria isolated from Moroccan sourdough bread. *International Journal of Agriculture and Biology, 7*(1), pp.67-70.

Zychowicz, C., Surazynska, A., Siewierska, B. and Cieplinska, T. (1974). Effect of *Lactobacillus acidophilus* cultures (*acidophilus* milk) on the carrier state of *Shigella* and *Salmonella* organisms in children. *Pediatria Polska, 49*, pp.997-1003.